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Currently, there is an increasing need for novel analgesics that are potent but lack
undesired side effects. Recent studies have shown that both 5-HT3 receptors and a2Badrenoceptors play a role in antinociception. MD-354, N-(3-chlorophenyl)guanidine, has a
high-affinity both for 5-HT3 and a2B-adrenoceptors and could be viewed as the first
example of a rather selective 5-HT3/a2B-adrenoceptorligand. MD-354, inactive by itself,
potentiates the antinociceptive effects of an inactive dose of clonidine in the mouse tailflick assay. An attempt to determine the underlying mechanism of this potentiating effect
was the purpose of the present investigation. The studies focused on an examination of: i)

xvi
MD-354 in the mouse hot-plate assay, ii) a more lipophilic analog of MD-354 in the tailflick assay, iii) various analogs of MD-354 with different binding profiles in both mouse
tail-flick and hot-plate assays. The present investigation suggests that both 5-HT3 and

a2~-

adrenoceptors are playing a role in the potentiation of clonidine analgesia by
arylguanidines such as MD-354.

Arylguanidines might represent a unique class of

analgesia-enhancing agents with a dual (5-HT3/a2-adrenoceptor)mechanism of action.

I. Introduction

The development of an analgesic that is effective but free of serious side effects
remains a major focus in the field of drug discovery. There are many drug classes that
have analgesic properties and are being used to reduce all degrees of pain. Examples of
these classes are nonsteroidal anti-inflammatory drugs (NSAIDs), local and general
anesthetics, opiates, and m-adrenoceptor agonists.' These agents' analgesic effects can
often be enhanced when used in combination with other analgesics or with one another.
Some of these agents have become very useful in the treatment of severe pain for patients
in post-surgery. Morphine and clonidine are popular analgesics that are currently being
used for this type of
Morphine was originally isolated in 1803 and was one of the first agents classified
as an opiate.' Morphine binds at opioid receptors and more specifically, mu opioid
receptors.4 It is a potent agent and is often referred to as a narcotic analgesic.' This means
that morphine can induce sleep and/or a state of narcosis in addition to its analgesic
effects.' Although morphine has been very successful in the treatment of severe pain, there
are some limitations with its use.
tolerance,

physical

c~nsti~ation.~-~

and

Some of the serious side effects of morphine are

psychological

dependence,

respiratory

depression,

and

Clonidine is an agent currently being used in regional anesthesia for the
management of acute post-operative pain, labor pain, or chronic pain.7 Clonidine binds
both at a2-adrenoceptors and imidazoline receptors.8 It binds nonselectively at

a2-

adrenoceptors, which means that it binds with similar affinity at all of the a2-adrenoceptor
subtypes (a2A,a 2 ~a2c).
,
Evidence shows that the analgesic effects of clonidine are due to
its partial agonist activity at a2-adrenoceptors.3 Similar to morphine, clonidine is a potent
analgesic but also has its limitations. Some of the side effects associated with this agent
are sedation, hypotension, and bradycardia.3'7 Due to its ability to lower blood pressure,
clonidine is also being used to treat hyperten~ion.~The sedative effects caused by
clonidine also can be considered a desired effect, and its induced sedative effect is useful
when clonidine is being used as an anesthetic. However, when it is being used as a postoperative analgesic, sedation can become a serious drawback.
Due to the undesired side effects associated with both morphine and clonidine, the
development of novel agents without these effects has become a major focus in the
improvement of analgesics. Several novel pathways have proven to play some role in
nociception. One example is the dopaminergic pathway. Dopamine receptors have been
n.~
Dz receptors are involved
related both to pronociception and a n t i n o c i ~ e ~ t i oSpecifically,
with inducing a n t i n o c i ~ e ~ t i oTherefore
n.~
the use of D2 agonists for pain relief can be a
possible novel pathway. Many of the classes in the serotonin receptor family also play a
role in nociception. It has been implicated that the 5-HT3 receptor class plays a significant
role in producing analgesia. However, there are currently available only a small number of
selective 5-HT3 receptor agonists. Since clonidine is already a well-used analgesic, another

3
therapeutic approach might be to reduce the side effects caused by this agent (i.e.,
sedation). Evidence shows that the sedative and hypotensive effects of clonidine are due to
the activation of the ~t~~-adrenoceptor
subtype.3 Recent studies have shown that the a 2 ~ adrenoceptor subtype contributes to antinociception but is not involved in ~ e d a t i o n5-HT3
.~
and ~t~~-adrenoceptors
have become potential pathways that could contribute to the
development of novel classes of analgesics without the drawbacks of morphine and
clonidine. In our laboratory, a novel series of arylguanidines has been developed and has
been shown to bind at 5-HT3 and/or a2-adrenoceptors. This exciting development can
possibly lead to a dual-mechanism analgesic agent. The purpose of the present study is to
investigate the antinociceptive effects, and the mechanism of action, of the arylguanidines.

11. Background

A. Pain
Due to the inconvenient side effects associated with current analgesic therapies,
pain is usually inadequately treated in most patients. Pain can be defined as "an unpleasant
sensory and emotional experience associated with actual or potential damage".I0 It consists
of a mechanism that prevents any potential damage that can occur to the tissue.''
Therefore, any potential analgesic cannot compromise or prevent this protective
mechanism from occurring which could lead to permanent damage. There are three types
of pain: nociceptive, inflammatory, and neuropathic pain.1091'
Nociceptive pain is the most
common type of pain experienced in everyday life. It is referred to as a usual response to a
brief noxious stimulus that induces little tissue

Inflammatory pain is usually

associated with trauma, infection, surgery, burns, or diseases that cause inflammation.
Neuropathic pain is a painhl response that is induced by damage involving the peripheral
or central nervous system and is usually associated with infection, tissue trauma, and
autoimmune diseases.1° In some cases, one mechanism can produce pain and in others,
different mechanisms can c o e ~ i s t . ' ~
Pain can also be classified into different categories, e.g. acute, chronic, and cancer.
Acute pain is defined as pain that is short with an identifiable cause and represents the
largest class of pain being treated. It involves mild to moderately severe pain that is

5

usually managed by the NSAIDS.'"~"'The side effects that accompany the use of NSAIDs
are gastrointestinal, renal, and liver toxicity. Opioids are also used when the NSAIDs fail
to manage moderate to severe acute pain. As mentioned earlier, the opioid class has its
own side effects that limit its use. Chronic pain is typically defined as pain that extends for
a duration of time in which the cause is u n k n o ~ n . ' ~Usually
,'~
it is the common cause of
major disability.'? Currently, there is no completely effective management or treatment for
chronic pain. However, opioids have been used in an attempt to manage this type of pain
as much as possible. Cancer pain is usually under-recognized or inadequately treated in
many cancer patients. 12 It can be acute or chronic depending on the stage of the disease.
The pain can come from various sources associated with cancer such as the tumor itself,
chemotherapy, radiotherapy, or surgery.'0
Pain can be associated with mechanical, chemical, and thermal stimuli. Mechanical
stimulus can cause intense pain such as pinching of the skin, traumatic injury, or
neuropathic

condition^.'^"^

Thermal stimuli involve the application of extreme

temperatures to the peripheral tissues, e.g. heat or cold. Chemical stimuli involve
application of acidic or basic chemicals to peripheral tissues.13 This latter type of stimulus
is the slowest of the three in producing nociceptive responses, and the pain produced is
inescapable.I3 After the noxious stimulus interacts with the peripheral tissues, the primary
afferent nociceptive pathways become activated. Nociceptor C and A6 primary afferent
fibers (PAFs) transduce the stimuli into electrical activity where the nociceptive
information is then integrated in the dorsal horn located on the spinal cord."'14 These two
types of PAFs both are nocisponsive, which respond to noxious chemical, thermal, and

6
mechanical stimuli.I4 The myelinated A6 fibers elicit the first phase of pain that is rapid
and sharp;9714
whereas the unmyelinated C fibers induce the second phase of pain which is
slower and

PAFs can directly activate the projection neurons that can relay this

information to the brain or indirectly activate them through the excitatory

inter neuron^.^"^

The nociceptive information can also be transferred by the PAFs by stimulating the
inhibitory interneurons. These interneurons can also interact with projection neurons,
excitatory interneurons, and the PAFs' terminals.9714
This process plays an important role
in the operation of the descending pathways of nociception. The descending pathways are
comprised of two mechanisms: descending inhibition and descending facilitation.
Descending inhibition is the primary mechanism that produces antinociception. This
response is produced by reducing the release of neurotransmitters from the PAFs'
terminals that aid in transmitting the pronociceptive information.9,1 1,14 The projection
neurons are inhibited by inhibiting the excitatory interneurons and simultaneously
stimulating the inhibitory interneurons.I4 This activity occurs postsynaptically to the
terminals of the P A F S . ~ ?Descending
'~
facilitation promotes pronociception. This pathway
elicits stimulation of the excitatory interneurons and projection neurons which leads to an
increase in nociceptive transmission.
The brainstem and other cerebral structures are the origin of the descending
pathways. 9,l 1,14,15 Many supraspinal regions play an essential role in the modulation of
nociceptive information. After the message is integrated in the dorsal horn, it is conveyed
to the brain through the spinothalamic and spinobrachial pathways." From the former
pathway, the activity is transferred through the thalamus to the somatosensory cortex."~14

7

The parabrachial region is connected to other supraspinal sites such as the hippocampus,
amygdala, and other regions which are involved in the nociceptive response.9,l 1,14 This
message is then integrated in the periaqueductal gray which plays a major role in
promoting and inhibiting pronociception.

'

Briefly mentioned earlier, the release of neurotransmitters is involved in pain
transmission. The most investigated neurotransmitters involved in descending pathways
are norepinephrine and serotonin (~-HT)." These two neurotransmitters can modulate the
flow of nociceptive information to the brain via its activity in the dorsal horn.
Norepinephrine is a part of the descending noradrenergic pathway and it interacts with
multiple classes of adrenoceptors

(P,

a l , a*). Serotonin is involved in the descending

serotoninergic pathway and this neurotransmitter interacts with the 5-HT receptor
superfamily (5-HT1-5-HT7).

B. 5-HT3 Receptors

1. Classification
Serotonin (5-hydroxytryptamine, 5-HT; 1) is a neurotransmitter that binds at
several 5-HT receptor populations and is involved with a variety of physiological effects in
the body. Some of these effects include vasoconstriction, vasodilation, body temperature
regulation, appetite, mood, platelet aggregation, sleep, and hormonal regulation.I6 These
different physiological effects are due to the ability of 5-HT to bind at a variety of 5-HT
receptors.
HT7).

5-HT receptors are classified as belonging to seven major families (5-HT1-5-

All of the 5-HT receptors are G-protein coupled receptors, except 5-HT3 receptors
which are ligand-gated ion channel (LGIC) receptors. There are major differences in
receptor function between G-protein coupled receptors and LGIC receptors. A G-protein
coupled receptor's functions are mediated via second messenger systems. This mechanism
is a multi-step receptor-effector cascade that elicits relatively slow cellular responses.
These receptors transmit this signal by activating a guanine nucleotide binding protein (Gprotein). G-Proteins consist of three subunits: a ,

P, y, in which the a subunit modulates

the activation of the G-protein. The ligand binds to the G-protein coupled receptor and
causes the G-protein to bind to a target enzyme. This enzyme then triggers a second
messenger that results in the cellular response. In the 5-HT family, the second messenger
systems that are involved are stimulation or inhibition of adenyl cyclase and stimulation of
phospholipase c . ' ~

A
n
-

Figure 1. G-Protein coupled receptor''

5-HT3 receptors are a member of the cys-loop superfamily which includes the
nicotinic acetylcholine (nACh) receptors, GABA*, and glycine receptors.

A LGIC

receptor's major function is to modulate the rapid transmission of synaptic nerve impulses
which are caused by the binding of neurotransmitters to the specific receptor. This process
results in the opening of an ion-selective pore.'6 In the case of 5-HT3receptors, 5-HT binds

S
'
, and ca2' to move through the
to the receptor and allows specific cations, such as ~ a ' ,I
lipid membrane.

Activation of these receptors produces various effects including

membrane depolarization, increase in intracellular ca2',

and the modulation of

neurotransmitter release.I8

2. Structure
The receptors in the cys-loop family typically are similar in structure. The most
extensively studied receptor is the nACh receptor. These pentameric receptors have five
homologous subunits (Figure 2) that consist of four transmembrane spanning domains

10
(TMl-TM4) (Figure 3), an intracellular loop between TM3 and TM4, and a large
extracellular N-terminal

It is suggested that the N-terminal domain is where

the ligand-binding domain is located.16 In this domain, there are 2 cysteine residues that
are linked by a disulfide bond. 5-HT3 receptors share about 20-30% amino acid sequence
identity with the nACh receptors.I6 since the crystal structure of the ACh binding protein
(AChBP) was recently determined, this facilitates the study of the 5-HT3 ligand binding
domain due to their structural similarities.

OOH

Figure 2. Quaternary structure of a LGIC receptor, and
the location of the TM2 lining the pore

Figure 3. Topology of a LGIC
receptor subunit

5-HT3 receptors have been classified into three subunits: 5-HT3~,5 - H T 3 ~and
, 5H T , ~ . 'However,
~
only the 5-HT3* and 5-HT3Bsubunits have been cloned.I6 The 5-HT3*
subunit has been cloned from a mouse neuroblastoma/Chinese hamster embryonic brain
cell hybrid, rat sympathetic neurons, human brain, guinea pig small intestine and ferret
colon.I6 The 5 - H T 3 ~subunit has been cloned from human fetal kidney, human small
intestine, and mouse and rat brain.I6 The 5-HT3A subunit is expressed in heterologous
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expression systems and has structural similarities with the other receptors in the cys-loop
s ~ ~ e r f a m i The
l ~ .protein
~ ~ ~ ~sequence
~
similarity between 5 - H T 3 ~and the a-subunits of
the other members is 22-30%.16 It has been suggested that the 5-HT3 receptor is a common
ancestor of all LGIC receptors because it is relatively similar to a 7 nACh receptor
subunits.I6 The 5 - H T 3 ~subunit consists of 487 amino acids and three potential Nglycosylation sequences that are located in the extracellular region.I6 These Nglycosylation sites could potentially be involved in the assembly of the 5-HT3 receptor.I6
5-HT3~
receptor is a protein that can form fully functional homomeric complexes. This
subunit plays a pivotal role in the pharmacological effects elicited by 5-HT3 receptors.
Recently, three variant forms of the 5-HT3* subunit have been identified in humans.22
These variants include normal, short, and long isoforms. The short variant is a polypeptide
unable to form functional homomeric ion channels, and they are coexpressed with the
normal 5 - H T 3 ~receptor.

It consists of 238 amino acids and forms only a single

transmembrane domain. It has a very short C-terminus but encodes the ligand binding
domain in the extracellular ~ - t e r r n i n u s .The
~ ~ long variant of 5 - H T 3 ~consists of 510
amino acids which is 23 amino acids longer than the normal variant. It also does not form
functional homomeric ion channels.22 These additional amino acids are inserted in the
extracellular loop between the TM2 and TM3 domain.22
The 5-HT3Bsubunit cannot form homomeric complexes but can form heteromeric
complexes with the 5-HT3Asubunit. This subunit has -45% sequence identity with its 5H T 3h~o m ~ l o ~The
. ' ~5-HT3Rsubunit has no function by itself, but elicits its function when
~
This receptor subunit has 441 amino acids and
it is coexpressed with the 5 - H T 3 subunit.

also has extracellular N-glycosylation sites as seen in the 5 - H T 3 ~
subunit. The 5-HT3B
subunit does not possess any of the structural features needed to induce the conductance
seen in the other LGIC receptors, and that causes its inability to form functional ion
channels." When this subunit forms a heteromeric complex with the 5-HT3* subunit, there
are no relatively significant changes in the normal pharmacological function of the 5-HT3
receptor. The only changes in function that the heteromeric complex shows are a larger
single-channel conductance and a decrease in ca2+permeability.20The 5-HT3c subunit was
just recently patented and its function is still unclear.'6123 This receptor shows -39%
sequence identity to its 5 - H T 3 h~ ~ m o l o ~ .It' ~has been suggested that the 5-HT3c subunit
contributes to the regulation of the 5-HT3 receptor's responses.23

3. Pharmacology
Evidence shows that 5-HT3 receptors are distributed throughout the CNS among
different species. In rats, these receptors are expressed in the forebrain, brainstem, and the
spinal cord. Some of these regions include the solitary tract nucleus, nucleus of spinal tract
of trigeminal nerve, dorsal horn of the spinal cord, and hippocampus.24~25
In mice, 5-HT3
receptors are distributed in similar regions of the spinal cord and forebrain as in the rats.
They are expressed in the hippocampus, dorsal tegrnental nucleus, trochlear nerve nucleus,
facial nerve nucleus, dorsal root ganglia, olfactory and somatosensory regions, and
throughout the cortical regions and limbic system.26 In humans, the majority of 5-HT3
receptors in the CNS are the 5-HT3Asubunit." These receptors are also distributed in the
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forebrain, hindbrain, medulla oblongata, spinal cord and, to a lesser extent, in the nucleus
accumbens, and striatum and substantia nigra.20
5-HT3 ligands have become important tools in studying the 5-HT3 receptor. For
instance, 5-HT3 antagonists are being used to determine thk distribution of these receptors
throughout the body. Various assays have been developed in order to differentiate between
5-HT3 agonists and antagonists. One of the first in vivo assays that was used is the von
Bezold-Jarisch reflex.

In this assay, the cardiovascular system is the primary site of

activity and the reflex causes a triad of responses that are apnea, bradycardia, and
hypotension.27 When a 5-HT3 agonist is administered it produces the von Bezold-Jarisch
reflex and mainly causes bradycardia. If an agent blocks this response in the presence of
the 5-HT3 agonist, then it can be referred to as an antagonist in this hnctional assay. This

in vivo assay is well known and is still currently being used to investigate 5-HT3 agonists
and antagonists. Another in vivo assay is the ferret and shrew emesis assay.28In this assay,
cisplatin, a vomiting-inducing agent, is administered to the animal to cause emesis.28A 5HT3 antagonist will prevent this emetic response from occurring and a 5-HT3 agonist
induces emesis.

Stimulation of 5-HT3 receptors has been shown to also produce

contractions in the gastrointestinal tract.

An important in vitro functional assay that

focuses on this response is the contraction of isolated guinea pig ileum. In this assay,
administration of 5-HT3 agonists produces contractions.

If an agent can block these

contractions it is referred to as an antagonist. In some cases, a 5-HT3 ligand can show
agonist activity in one functional assay and antagonist activity in another assay. The
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determination of these ligands has played a pivotal role in fully understanding 5-HT3
receptors and their many functions.

4. Ligands and Structure-Activity Relationships (SAR)
a) Agonists
Over the years a variety of drug classes have been shown to bind selectively to 5HT3 receptors. Both agonist and antagonists have been studied and some antagonists are
currently being used clinically in the treatment of a variety of disorders. To date, there are
few available 5-HT3 agonists to study their pharmacological effects. The first class of
agonists found to bind to these receptors is the tryptamines. 5-HT (I), a member of this
class, binds to 5-HT3 receptors nonselectively and with moderate affinity (Ki =1,000 n ~ ) . ~ ~
2-Methyl 5-HT (2) was found to display more selectivity for 5-HT3 receptors than 5-HT
. ~ ~ 5-HT is one of the few
but binds with slightly lower affinity (Ki ~ 1 , 3 5 0n ~ ) 2-Methyl
currently available 5-HT3 agonists

being used. Recent investigations have shown,

however, that 2 binds at 5-HT6 receptors (Ki = 45 nM) with higher affinity than it displays
for 5-HT3 receptors. 29
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Different analogs of 5-HT were studied and it was found that trimethylation of the terminal
This
'
amine (5-HTQ, 3) resulted in a highly selective 5-HT3 agonist (K; = 75 n ~ ) . ~
quaternary amine binds with a ten times higher affinity than 5-HT (I), but has difficulty in
penetrating the blood-brain barrier (BBB) and is of limited k e for in vivo studies."
The arylbiguanides represent another class of 5-HT3 agonists that are
nontryptamines and selective for this receptor.

Phenylbiguanide (PBG, 4) was the first

agent of this class to be developed and it displayed moderate affinity (K; =1,200 nM)
comparable to 5-HT. m-Chlorophenylbiguanide (m-CPBG, 5; Ki = 17 nM) was found to be
a higher affinity agent than P B G . ~Structure-activity
~
relationship (SAR) studies were
conducted by Dukat et

and the major focus was the modification of the aryl

substituents and the biguanide chain. In aryl substitution, analogs with different functional
groups at various positions on the phenyl ring were studied (Table 1).25The primary goal
of this study was to examine the electronic and lipophilic character of these substituents
and their effect on affinity.23 Addition of a chloro group at the 2- or Cposition resulted in
higher affinity than PBG but in lower affinity than m-CPBG (6, 7, Ki = 62 and 200 nM,
respectively). Replacing the 3-chloro group with a nitro (8) or trifluoromethyl (17) group,
stronger electron-withdrawing groups, resulted in a decrease in affinity (Ki = 220 nM and
700 nM, r e ~ ~ e c t i v e l ~ ) Also,
. ~ ~ . ~replacing
'
the chloro group with a methyl group, an
equally lipophilic and more electron-donating group, resulted in decreased affinity (9, Ki

= 780 nM). Replacement by a 4-methyl group abolishes affinity (10) but adding a chloro
group at the 3-postion to this derivative enhances affinity (11, Ki = 225 nM). Addition of a
methoxy group to the 2-position and a chloro group in the 5-position also enhances affinity
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when compared to PBG (12, Ki =I26 nM). The 2-napthyl derivative 13 (Ki = 12 nM) binds
with high affinity that is similar to m-CPBG. From this study it was found that the 3chloro substituent was optimal for binding.

In separate studies, it was found that

incorporating chloro substituents at the 4- andlor 5-posi'tions resulted in even higheraffinity agents (14, 15, 16, Ki = 12, 1.8, and 2.7 nM, respectively).30

Table 1. Observed Binding Affinities of Arylbiguanides for 5-HT3 ~ e c e p t o r s . ~ ~

4-12 and 14-17

13

17
Next, the biguanide chain was modified. Dimethylation of the terminal amine
~'
derivatives were studied and
resulted in abolished affinity (18; Ki > 10,000 n ~ ) . Various
it was shown that any further modification (with one exception) of the biguanide chain also

19, (Ki = 40 nM) displayed
abolished affinity.30 However, the ~-(2-~hen~leth~l)~uanidine
high affinity.30 More importantly, it was found that the entire biguanide chain was not
necessary for binding and could be shortened; this resulted in the arylguanidines.30

18

19

This novel class of compounds, the arylguanidines, was found to bind with
affinities comparable to the arylbiguanide~.~~
Between the two classes parallel structural
changes led to parallel shifts in affinity.31 SAR studies were conducted and both aryl
substitution and the guanidine moiety were examined (Table 2). As with the
arylbiguanides, a chloro group at the 3-position is optimal. m-Chlorophenylguanidine
(MD-354, 21) binds with high affinity and was the first agent developed in this class (Ki =
35 n ~ ) . ~Also,
'
as with the arylbiguanides, high affinity was not retained when the chloro
group was replaced with a trifluoromethyl group (24, Ki = 5700 nM). Addition of chloro
groups at the 4- andlor 5-positions led to higher affinity agents as in the arylbiguanide
series (27, 28, 29, Ki = 3.1, 5.0, and 0.7 nM, respectively). Conformationally constrained
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analogs of MD-354 were also examined as possible ligands.32 Benzimidazole 30 and
quinazoline 31 were developed and it was found that only the quinazoline displayed high
affinity (K; = 725 and 34 nM, respectively). Although some of the arylguanidines bind at 5HT3 receptors with high affinity, they might have difficulty penetrating the BBB.
Theoretically, an agent should possess a Log P value that falls in the 1.5 to 2.5 range in
order to penetrate the BBB.'~MD-354 (21) has a Log P value of -0.64 which suggests that
this agent will have difficulty penetrating the B B B . ~This
~
could limit the use of
arylguanidines in behavioral studies, and their potential clinical use for treating central
disorders.

Table 2. Observed Binding Affinities of Arylguanidines at 5-HT3 ~ e c e ~ t o r s . ~ ~ " ~

b) Antagonists
When compared with the 5-HT3 agonists, there are definitely more available
antagonists for research and on the

5-HT3 antagonists are currently being used

clinically in the treatment of irritable bowl syndrome and as antiemetics.

These

antagonists include zacopride (32), tropisetron (33), ondansetron (34), and granisetron
(35), just to mention a few representative examples.34 Zacopride (32) is an extremely
potent blocking agent that binds at 5-HT3 receptors (Ki= 0.1-1.9 nM), but it also acts as an
agonist at 5-HT4 receptors (Ki= 1.1 n ~ ) Tropisetron
. ~ ~
(33) (formerly known as ICS 205930) was one of the first clinically used antiemetics among the 5-HT3 antagonists. It acts as
an antagonist at both 5-HT3 and 5-HT4 receptors (Ki= 0.4-3.2 and 930 nM, respectively).35
Both ondansetron (34) and granisetron (35) bind selectively at 5-HT3 receptors with high
affinity (Ki= 0.8-13 and 0.3-4.2 nM, respectively).35 Radiolabeled versions of these agents
have also been used as radioligands in binding studies, and were involved in determining
the distribution of 5-HT3 receptors in the CNS." These agents also are useful in
evaluating the functional roles of these receptors.

f i ~ ~
Zacopride (32)

Ondansetron (34)

Tropisetron (33)

Granisetron (35)

5-HT3 receptors have become major targets in the development of novel agents for
the treatment of a variety of disorders due to their general lack of side effects.34
Ondansetron (34) is being used clinically to relieve nausea and vomiting associated with
cancer chemotherapy, radiation, and a n e ~ t h e s i a . ~ '5-HT3
, ~ ~ antagonists block emesis by
producing antagonism of the receptors located at central sites.36 Ondansetron (34) is
highly effective but does not completely eliminate nausea and vomiting.34When compared
with previous antiemetics (i.e., scopolan~ine),the 5-HT3 antagonists do not cause any
sedation.34 5-HT3 receptors also play a role in anxiety, and it is suggested that 5-HT3
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antagonists could be used as potential a r ~ x i o l y t i c s .In
~ ~clinical
'~~
studies, however, it was
shown that the 5-HT3 antagonist granisetron (35) was not as effective as the
benzodiazepines as an anxiolytic. However, these antagonists did not produce any of the
side effects, such as sedation and rebound anxiety following chronic treatment, seen with
the b e n z ~ d i a z e ~ i n eAnother
s . ~ ~ area in which 5-HT3 receptors are involved is gut motility.
The stimulation of these receptors could cause diarrhea, which is commonly referred to as
intestinal hyperrnotility.36This is usually associated with irritable bowel syndrome. 5-HT3
antagonists could potentially be used in the treatment of diarrhea. On the other hand, 5-

HT3 agonists could also be used in the treatment of constipation.23 Since it is suggested
that stimulation of 5-HT3 receptors increases intestinal motility in this disorder, it could be
beneficial to use a 5-HT3 agonist which is effective and does not induce emesis and
diarrhea.23
As discussed earlier, 5-HT3 receptors have been implicated as playing a role in
nociception. This is summarized in Table 3; earlier radioligand binding studies showed that
5-HT3 receptors are located on sensory nerve endings in the periphery, on the soma and
axon membranes of sensory neurons, and on primary afferent terminals in the spinal
~ o r d . ~It~was
, ' ~also shown that 5-HT3 receptors located on peripheral sensory neurons are
involved in inflammatory, but not mechanical or thermal, pain in animal models.36 For
example, Giordano et

showed that the subcutaneously (s.c.) administered 5-HT3

receptor antagonist tropisetron (33) did not produce analgesia in thermal and mechanical
nociceptive tests. However, tropisetron produced analgesia in the formalin test, a chemical
nociceptive test.40 In this test, formalin induces inflammatory pain which is blocked by

tropisetron. Also in this study, both central and peripheral 5-HT3 receptors were examined.
When tropisetron was injected by intracerebroventricular (i.c.v.) administration, it was
found to be ineffective in producing analgesia in acute thermal, mechanical, and chemical
pain tests.40 The lack of analgesic activity of 5-HT3 receptor antagonists in thermal and
/

mechanical pain tests supports the hypothesis that 5-HT3 receptors do not mediate the
transmission of nociceptive signals.40 However, the antinociceptive effect produced by 5HT3 antagonists in the formalin-induced pain test further suggests that 5-HT3 receptors
induce a response to inflammatory pain.40 These results also suggest that supraspinal 5HT3 receptors might not be involved in mediating this response since these antagonists
were administered (i.c.v.) directly into the brain and did not produce a n t i n o c i ~ e ~ t i o nIn. ~ ~
a separate study, the 5-HT3 receptor agonist 2-methyl 5-HT (2) was also analyzed in the
formalin-induced test.41 2-Methyl 5-HT was administered it., and found to produce an
antinociceptive response.4' This antinociceptive response was reduced by i.t. administered
MDL-72222, a potent 5-HT3 receptor antagonist.41 According to these results, it further
suggests that spinal 5-HT3 receptors induce antinociceptive responses to inflammatory
pain. This analgesic activity could also be reduced by ketanserin (5-HT2 antagonist),
naloxone (opioid antagonist), and bicuculline (GABAA antagonist).41 Because this 5-HT3
receptor-mediated antinociception could be attenuated by various other antagonists, this
suggests that the 5-HT3 descending inhibitory system is interacting with 5-HT2, GABAA,
and opioid receptors. When 2-methyl 5-HT (2) was administered i.c.v., it did not produce
any antinociceptive activity.4' This also supports the idea that supraspinal 5-HT3 receptors
do not mediate nociceptive responses to inflammation. This receptor has been shown to
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mediate a component of the nociceptive response to subacute and chronic inflammation
caused by 5-HT and other noxious agents, however the initial phase of inflammation and
acute pain does not seem to be reliant on the 5-HT3 receptor.392-Methyl 5-HT and 5-HT
were also analyzed in the writhing test.39 This test was used to study visceral 5-HT3
receptors' role in modulating nociceptive responses. In this study intraperitoneally (i.p.)
administered 5-HT produced a dose-dependent nociceptive writhing response that was
blocked by tropisetron (33) (1 mgikg, i.p.).39 However, 2-methyl 5-HT (2) did not produce
any nociceptive responses or writhing when administered alone. But, when 2-methyl 5-HT
was administered following a low dose of 5-HT, it showed enhancement in the
antinociceptive activity of ~ - H T . ' These
~
results suggest that visceral 5-HT3 receptors
could play a role in mediating inflammatory pain, but it seems to be dependent on other
mechanisms to elicit its activity. This idea is demonstrated when 2-methyl 5-HT alone did
not produce a nociceptive writhing response. Another possible explanation could be that
since tropisetron is a 5-HT3 and 5-HT4 receptor antagonist, this specific dose could be
interacting with 5-HT4 receptors which might be involved in this nociceptive activity.
5-HT3 receptors were also shown to have a possible role in spinal nociception. This
hypothesis has been studied via thermal pain tests in rodents. In a study by Glaum et
it was shown that intrathecally (i.t.) administered 5-HT produced antinociceptive activity
in the hot-plate test. This activity was attenuated by i.t. administered tropisetron (33) (0.01
This study further supports the concept that 5-HT3 receptors mediate spinal
analgesia. As mentioned earlier, various 5-HT3 receptor antagonists were analyzed in the
hot water bath test in rats for possible antinociceptive activity.40These antagonists did not
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Table 3. Summary of 5-HT3 Ligand Activity in Various Animal Nociceptive Tests.
Model
Inflammatory
pain
Formalin test

Agents

Tropisetron
MDL-72222
Ondansetron
2-Methyl 5-HT

Agonist/
Antagonist

Antagonist
Antagonist
Antagonist
Agonist

Writhing test

Hot platel
Hot water
bath

Tropisetron
MDL-72222
Ondansetron

Antagonist
Antagonist
Antagonist

Agonist

Tail flick

Mechanical

Route of
S ~ e c i e s Admin.

rats
rats
rats
rats

S.C.
i.c.v.
i.t. '
i.t.

rats
mice

i.c.v.
i.p.

rats
rats
rats

S.C.

rats

i.t.

i.c.v
i.t.

PBG

Agonist

rats

Tropisetron

Antagonist

rats
rats
rats

i.c.v.
i.t.

S.C.

i.c.v.
i.t.

Antagonist rats

i.t.

Zacopride
2-Methyl 5-HT

Antagonist rats
Agonist
rats

i.t.
i.t.

PBG

Agonist

i.t.

rats

Analgesic Activity

Yes
no
no
yesiblocked by
5-HT3, 5-HT2,
opioid,GABA
antagonists
no
produces no
nociceptive
responses alone
no
no
noiblocks
analgesic
effect of 5-HT
yes/ reduced by
5-HT3, 5-HT2,
opioid, and
GABA antagonists
no
Yes
no
no
nohlocks i.c.v.
morphine-induced
analgesia
nohlocks i.t.
2-Methyl 5HT
no
yes/ blocked by
5-HT3, GABA, a2
and a-adrenoceptor
antagonists
no

Ref.
40
40
40
41

41
39

40
40
40,42

41

41
43
40
40
40,46

40,42
40
42-44

43

Tropisetron
MDL-72222
Ondansetron

Antagonist
Antagonist
Antagonist

rats
rats
rats

S.C.
i.c.v.
i.t.

4.0
40
40

2-Methyl 5-HT

Agonist

mCPBG

Agonist

rats
rats
rats

i.c.v.
i.t.
i.t.

48
48
49

yes/ blocked by 5-HT3
antagonists
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produce any antinociceptive activity when administered subcutaneously (s.c.) or via the
i.c.v. route.40 5-HT produces analgesic effects through influence on the CNS, and these
effects can be mimicked by 2-methyl 5-HT (2).36)39TO further characterize the role of 5HT3 receptors in spinal analgesia, 2-methyl 5-HT was studied in the hot-plate test.
f

Giordano et

showed that i.t. administered 2-methyl 5-HT produces antinociception in

rats. This activity was reduced by 5-HT3, 5-HT2, opioid, and GABAA

This

study also showed the involvement of other systems with 5-HT3 receptors in mediating
spinal analgesia. However, i.c.v. administered 2-methyl 5-HT did not produce
a n t i n o ~ i c e ~ t i o nThese
. ~ ' results suggest that supraspinal 5-HT3 receptors also might not
mediate spinal analgesia. Another study showed that i.t. administered PBG (4), a 5-HT3
agonist, produced analgesic activity.435-HT3 receptor ligands have also been analyzed in a
second thermal test, the tail-flick test. This behavioral test focused on analgesic activity
that was elicited by spinal 5-HT3 receptors.

In a study by Glaum et

both i.t.

administered 5-HT and 2-methyl 5-HT produced antinociceptive activity that could be
blocked by i.t. administered MDL-72222 and tropisetron (33). This study further supports
the concept that 5-HT3 receptors mediate spinal analgesia. In a separate study, i t .
administered 2-methyl 5-HT produced antinociception in mice that was also blocked by 5HT3 and GABAA antagonists.44 The antinociceptive activity was only partially blocked by
phalcofen (GABAB antagonist).44 In earlier studies, it was suggested that 5-HT3 receptors
could mediate the release of GABA which elicits the antinociceptive activity.44 These
results support this idea since both GABAA and GABAB antagonists can block the
antinociceptive activity produced by 2-methyl ~ - H T . ~ ~
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Noradrenergic

receptors

also play

a role

in mediating

5-HT-mediated

antino~ice~tion."It was previously shown that i.t. administered norepinephrine and 5-HT
produce a synergistic effect." Sawynok et

showed that both 5-HT and 2-methyl 5-

HT's antinociceptive activity could be reduced by phentolamine (nonselective a-AR
I

antagonist) and yohimbine (a2-AR antagonist). PBG (4) was also analyzed in the tail-flick
test for possible antinociceptive activity. When administered it., unlike 2-methyl 5-HT (2),
PBG did not produce a n t i n o ~ i c e ~ t i oThe
n.~~
difference in activity with 2-methyl 5-HT and
PBG suggests that 5-HT3 receptors do not directly mediate spinal analgesia. 2-Methyl 5HT could mediate the release of 5-HT, which then activates the 5-HT3 receptors. Another
possibility could be that 2-methyl 5-HT is inducing antinociception via another serotonin
receptor subtype. The latter possibility is less likely because analgesic activity produced by
2-methyl 5-HT can be blocked by MDL-72222 which is selective for 5-HT3 receptors.
Since it has been implicated that 5-HT mediates morphine-induced antinociception, a
specific role for 5-HT3 receptors has been studied.46 It has been shown that i.t.
administered morphine produces antinociception that can be blocked by t r ~ ~ i s e t r oIn
n .a~ ~
later study, i.t. administered tropisetron (33) also blocked i.c.v. administered morphineinduced antinociceptive activity.47 It is apparent that 5-HT3 receptors participate in a more
complex system that mediates antinociception which involves a variety of receptor
families. Figure 4 illustrates the overlapping of the different receptors and their possible
roles in mediating analgesia.9
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DESCENDING INHIB1716N

DESCENDING FAC1LITAIIOU

Figure 4. Schematic diagram of 5-HT serotonergic system modulating n o c i ~ e ~ t i oThis
n . ~ figure is
used to show the involvement of the serotonergic system with other neurotransmitters.

Mechanical nociceptive tests have been used to study possible involvement of 5HT3 receptors in modulating an antinociceptive response to mechanical noxious stimuli in
rodents. In a mechanical test, nociceptive responses are elicited by applying an increasing
pressure to the paw or dorsal side of the distal tail of a rodent until a squeak or withdrawal
response is

As seen in certain other nociceptive tests, 5-HT3 receptors do not

2-Methyl 5-HT (2), administered i.t.
seem to be conclusively involved in antino~ice~tion.~'
and i.c.v., was studied and did not produce an antinociceptive response in the paw pressure
test.48 In another study, mCPBG (5) and 5-HT were also analyzed in the paw pressure
test.49Both i.t. administered 5-HT and mCPBG produced a dose-dependent antinociceptive
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response which was blocked by tropisetron and g a n i ~ e t r o n .5-HT
~ ~ produced higher
antinociceptive effects than mCPBG, an agent which is more selective for 5-HT3 receptors
than ~ - H T This
. ~ ~suggests that 5-HT3 receptors might be partially involved in producing
an antinociceptive response to a mechanical stimulus.49In the paw pressure test, two 5-HT3
agonists, 2-methyl 5-HT (2) and mCPBG, showed different activities. Since mCPBG
binds with higher affinity at 5-HT3 receptors, the findings suggest that the mechanism
involved in the 5-HT-induced antinociception could be direct activation of 5-HT3
receptors. This activation could lead to the partial antinociceptive response seen by
mCPBG. It has also been shown that mCPBG is involved with the dopaminergic pathway
and causes the release of d ~ ~ a n i i n This
e . ~ ~could also play a role in the partial
antinociceptive

actions

of

mCPBG

since dopamine

has

been

implicated

in

a n t i n o c i ~ e ~ t i o nCurrently,
. ~ ' ~ ~ results from animal studies that deal with the actual role of
5-HT3 receptors in modulating nociception are controversial. Although there is substantial
evidence to suggest that 5-HT3 receptors could mediate spinal analgesia, the mechanism of
this activity is still unclear. Thus, additional studies are required before it can be concluded
that 5-HT3receptor agonists may or may not be useful in the treatment of acute pain.
Many clinical studies have been conducted to determine the possible clinical utility
of 5-HT3 receptor antagonists in the treatment of acute pain. Tropisetron (33) was one of
the first selective 5-HT3 receptor antagonists to be used as a potential treatment of
rheumatism, a condition characterized by inflammation or pain in muscles, joints, or
et a1.52 showed that tropisetron was effective compared with
fibrous t i ~ s u e . ~Ferber
'

placebo in reducing pain in patients with fibromyalgia in a double-blind study. The most
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frequent complaints reported were constipation and h e a d a ~ h e . ~Muller
'
et ~

1reported
. ~ ~

that only up to 50% of patients with fibromyalgia actually responded to tropisetron with a
reduction of pain. It was also hypothesized that 5-HT plays a key role in producing pain
during an acute migraine attack.38In an open pilot study, 5 out of 6 patients experienced a
rapid relief of pain when treated with granisetron ( 3 ~ ) In. ~further
~
studies, other 5-HT3
receptor antagonists (i.e., ondansetron (34) and tropisetron (33)) did not consistently
relieve the pain caused by a migraine attack.38 Stratz and ~ u l l e showed
r ~ ~ that tropisetron
was effective in the local treatment of rheumatoid arthritis, tendinopathies, periarthropathies, and myofasical pain syndrome. Overall these studies have shown that 5-HT3
receptor antagonists can be useful in situations linked to inflammatory stimuli.
It has been shown that 5-HT3 receptors might be involved in the modulation of
nociception. The 5-HT3 receptor agonist %-methyl 5-HT showed analgesic activity in the
inflammatory and thermal but not mechanical tests, whereas another 5-HT3 receptor
agonist, PBG, did not produce analgesia. However, the more selective 5-HT3 receptor
agonist mCPBG produced analgesic activity in the mechanical test. The 5-HT3 receptor
antagonists only produced analgesic activity in the formalin-induced inflammatory test
when administered via the S.C.route. From these results, demonstrating a role for 5-HT3
receptors in mediating nociception has been quite difficult. Inconclusive findings with 5HT3receptor agonists could be related to their non-selectivity, low-affinity, andlor inability
to penetrate the blood-brain barrier; thus, there is a definite need for the development of
potent, centrally acting 5-HT3 agonists that have the ability to penetrate the blood-brain
barrier. This controversy could also be due to factors dealing with the nociceptive tests
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that were used. Other factors include route of administration, species, and 5-HT3 ligand
used. Additional studies with more lipophilic 5-HT3 receptor agonists would certainly
allow a clearer understanding of the involvement of 5-HT3 receptors in pain.

I . Classification
The adrenoceptors, a receptor family that has been extensively studied over the
years, are membrane receptors that belong to the superfamily of G-protein coupled
receptors (GPCRs). They bind the endogenous catecholamines, norepinephrine (36) and
epinephrine (37), which elicit a variety of physiological effects in both the central and
peripheral nervous systems.55 Some of these effects include control of blood pressure and
blood flow, neuronal modulation, digestion, respiration, reproduction, pupil dilation and
contraction, and energetic r n e t a b ~ l i s m . ~Norepinephrine
~

is released from the

noradrenergic postganglionic nerve terminals, and both norepinephrine and epinephrine are
secreted in the adrenal medulla.55

Norepinephrine (36)

Epinephrine (37)

The adrenoceptors are divided into two broad categories, a - and ~ - a d r e n o c e ~ t o r s . ~ ~
a-Adrenoceptors can be further divided into a , - and a2-adrenoceptors.56 The a and

P

adrenoceptors were initially classified according to the rank order of potency of a series of
adrenoceptor agonists.57For the a-adrenoceptors, epinephrine (37) = norepinephrine (36) >
isoproterenol (38) in terms of potency, and for the P-adrenoceptors, isoproterenol >
epinephrine > norepinephrine.57 a-Adrenoceptors mediate mostly excitatory functions that
include vasoconstriction, uterine musculature contraction, urethra contraction, and pupil
s
dilation, and one inhibitory function, intestinal r e l a x a t i ~ n . ~p~- ~ d r e n o c e ~ t o rmediate
mostly inhibitory functions that include vasodilation, uterine musculature relaxation,
bronchodiliation, and an excitatory fbnction, cardiac function.55 a2-Adrenoceptors are
classified into three subtypes: a2*-, a 2 ~ - and
,
a2c-adrenoceptor subtypes. As mentioned
earlier, GPCRs mediate their physiological effects via second messenger systems (Figure
5). In the case of a2-adrenoceptors, the second messenger systems that are involved are

inhibition or stimulation of adenylyl cyclase, activation of receptor-operated K+ channels,
and inhibition of voltage-gated ca2+ channel^.'^ It has been suggested that other G-protein
dependent signaling pathways are mediated by activation of phospholipase D, stimulation
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of phospholipase A2 activity, and increased intracellular ca2+ a ~ a i l a b i l i t ~The
. ~ ~a.2~- ~
adrenoceptors are coupled to Gi/, types of G-proteins, which cause the inhibition of
adenylyl cyclase and lead to a decrease in cAMP levels.' These G-proteins are sensitive to
inactivation by pertussis toxin, which prevents the dissocigtion of the a subunit fiom the
subunit.58 However, it has been shown that a2-adrenoceptors are also coupled to the
stimulation of adenylyl cyclase via G,-proteins in some cells transfected with

a2-

adrenoceptors which leads to an elevation in CAMP levels.59 All three subtypes are
involved with decreasing cAMP levels, but it has been shown that only

a 2 ~and
-

a2c-

adrenoceptors inhibit ca2+channels and activate K+ channels.56

Figure 5. Schematic diagram of the G-protein cycle.59 PTX: Pertussis toxin and CTX: cholera
toxin.

2. Structure

The arrangement of the structure of a2-adrenoceptors corresponds to a model of the
protein rhodopsin, which has been extensively studied, and several subtypes have been

33
identified.'"

general,

Q-adrenoceptors

have

seven

transmembrane-spanning

hydrophobic regions (TM 1-TM7), with hydrophilic intracellular and extracellular
The transmembrane regions are made up of 20- to 25-amino acids forming alpha helices
that are embedded in the membrane.8 The &-adrenoceptor subtypes share about 75%
amino acid identity in their transmembrane regions.' The largest difference among the a2adrenoceptor subtypes occurs in the N-terminus and in the third intracellular loop between
TM5 and T M ~ Among
. ~ ~ the subtypes, they share less than 25% sequence identity in the
third intracellular loop.58 The third intracellular loops of the three subtypes vary in
sequence and in the number of amino acids: a2*-adrenoceptors consist of 157 amino
acids, a2B-adrenoceptorsconsist of 173 amino acids, and azc-adrenoceptors consist of 148
amino acids (Table 4)."

Table 4. Summary of a2-Adrenoceptor Subtype ~haracteristics.~~
a7A

a?,-

Human chromosome
Structure
number of amino acids
transmembrane domains
number of amino acids in
third intracellular loop
glycosylated
palmitoylated
Second messenger systems

G$,: L. CAMP.
inhibit ca2'
channels, open
K' channels

Gil,:

CAMP

Gi,,: CAMP.
inhibit ca2'
channels, open
K' channels
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Interestingly, the third intracellular loop of the a2B-adrenoceptorsubtype contains
a higher number of glutamic acid residues (13%) when compared to azA-adrenoceptors

(6%) and a2c-adrenoceptors (3%).60 In this region, which is only seen in
adrenoceptors, there is a stretch of 12 consecutive glutapic acid residues."

a2~-

The third

intracellular loop is about two to three times longer in the a2-adrenoceptors than in the
corresponding loops of the a , - and P-adreno~e~tors.'~
The second and third intracellular
loops are involved with G-protein

interaction^.^^

The @A-adrenoceptorsubtype consists of

450 amino acids and is glycosylated on the N-terminus and palmitoylated on the CThe ~x~~-adrenoceptor
subtype also consists of 450 amino acids and is
palmitoylated on the C-terminus but is not glycosylated, whereas the a2c-subtype consists
of 461 amino acids and is only glycosylated on the

terminus.^^"^

The palmitoylated

cysteine residue in the a z ~and
- azB-adrenoceptorsattaches the receptor to the lipid bilayer
of the cell membrane." It is suggested that some of the TM regions form a ligand-binding
pocket located in the upper part of the hydrophobic core of the receptor (Figure 6).58 There
is a disulphide bridge between two cysteine residues in TM3 and the second extracellular
loop that is important for maintaining the overall protein structure.58

Extracellular

Plasma
membrane

Figure 6. Model of a ligand binding to a GPCR.~*

All of the a2-adrenoceptor subtypes have been cloned from human, rat, mouse, and

guinea pig

source^.^^'^^

The human a2-adrenoceptor subtypes have been designated a2-

C10 ( a 2 ~ ) ,a2-C2 (a2B), and a2-C4 (a2c).

These designations are based on their

chromosomal location on the human gene that encodes these subtypes.57These subtypes
share approximately 50% amino acid identity. Also, the porcine and bovine a 2 ~ -chicken
,
a2,4-, opossum a2c- and fish azc-adrenoceptors are orthologs and have been cloned.58The
rodent a2~-adrenoceptorwas initially classified as a new subtype, the azD-adrenoceptor,
but is now acknowledged as the rodent homolog of the human aA-adrenoceptorsubtype.58
The difference in these two subtypes is their affinity for an a2-adrenoceptor ligand. The
rat a20-adrenoceptor subtype has a lower affinity for the nonselective a2-adrenoceptor
antagonist yohimbine (39) than does the human ~cz~-adrenoce~tor.~*

Yohimbine (39)

3. Pharmacology
a*-Adrenoceptors play a major role in mediating several physiological effects in
the CNS. The various a2-adrenoceptor subtypes are distributed throughout the brainstem
and spinal cord. In rats and mice, a2-adrenoceptors are localized throughout the same
regions in the CNS." The arA-adrenoceptor subtype is located in the brainstem, cerebral
cortex, locus coeruleus, amygdala, pontine nuclei, nucleus tractus solitarii, dorsal horn, and
subtype is found mainly in the thalamus,
the dorsal root ganglia.6'?62The ~t~~-adrenoceptor
and the ~t~~-adrenoceptor
subtype is found in the olfactory bulb, cerebral cortex,
hippocampus, striaturn, and dorsal root

In humans, the &*-subtype is

distributed in the cerebral cortex, brainstem, hippocampus, amygdala, locus coeruleus, and
dorsal root ganglia. 55,64,65 The a2B-adrenoceptor subtype is distributed in the thalamus,
dorsal root ganglia, and throughout the spinal cord, and the azc-adrenoceptor subtype is
distributed in the cerebral cortex and lumbar spinal cord.55,64,65
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Both a2-adrenoceptor agonists and antagonists have been analyzed to study the
functions of a2-adrenoceptors. There are various functional assays that have been used in
order to characterize a2-adrenoceptor ligands as agonists or antagonists. a2-Adrenoceptors
modulate blood pressure, therefore one in vivo assay that has been used is a measurement
I

of pressor responses in a pithed rat

In this model, the spinal cord of the rat is

severed by inserting a steel rod, which acts as a stimulating electrode, down the spinal
Then, arterial pressure is monitored by cannulating the right carotid artery. When
an a2-adrenoceptor agonist is administered, it causes a decrease in blood pressure (or a
hypotensive effect).66 Thus an @-adrenoceptor antagonist blocks this decrease in blood
pressure. An alternative method to studying pressor responses is in anaesthetized rats.67
The only difference in this model is that the rats are anaesthetized with pentobarbital
instead of severing the spinal cord. As seen in the pithed rats, a2-adrenoceptor agonists
produce a hypotensive effect.67An in vitvo assay used for Q-adrenoceptors is contraction
of the saphenous vein.56 In this assay, an e-adrenoceptor ligand is administered and if it
causes the saphenous vein to contract, it is referred to as an agonist.56 a2-Adrenoceptor
ligands are characterized as antagonists if they can block this contraction. These functional
assays have been helpful in further understanding the physiological effects produced by
a2-adrenoceptors.

4. Ligands and SAR
a) Agonists

Currently, there are several drug classes that bind at a2-adrenoceptor subtypes
nonselectively. Both nonselective agonists and antagonists have a variety of therapeutic
applications.

The first drug class found to bind at a2-adrenoceptors was the

phenylethylamines.68 This class consists of the two endogenous agonists norepinephrine
(36, Ki = 81 nM) and epinephrine (37, Ki = 15 n ~ )However,
. ~ ~ these two agonists bind
nonselectively at a , - , a f - , and P-adrenoceptors. Increasing the steric bulk of the Nsubstituent to ethyl (40), isopropyl (38), or tert-butyl (41) eliminates affinity for a 2 Maintaining
~
the catechol moiety is also important for
adrenoceptors (Ki > 1 0 , 0 0 0 ) . ~

binding at these receptors.68 Removal of the P-hydroxyl group usually reduces the affinity
at a2-adrenoceptors, but dopamine (42, Ki = 250 nM) retains high affinity." The
phenylethylamines have been shown to possess higher affinity for P-adrenoceptors when
compared to a2-adrenoceptors.

Dopamine (42)
The next major class of compounds that binds at a2-adrenoceptors is the
imidazolines. Most of the representative agents in this class are partial agonists, whereas
others are either full agonists or antagonists.68In the imidazoline class, the presence of a
catechol moiety results in high affinity agents but is not required for binding at a2adren~ce~tors."An important nonselective a2-adrenoceptor agonist in this class is
clonidine (43, Ki = 1.8 nM); 43 is an a m i n o i r n i d a ~ o l i n e . ~In
~ > ~general,
~
the
aminoimidazolines are highly selective for a2-adrenoceptors and when they bear
substituents at the 2- andlor 4-positions they can readily cross the blood-brain barrier.68An
analog of clonidine, ST-91 (44), was also found to bind at a2-adrenoceptors with high
affinity as seen with clonidine and also behaves as an a2-adrenoceptoragonist.@ Since

Clonidine (43)

ST-91 (44)

clonidine (43) possesses such high affinity at a2-adrenoceptors, its structure has been used
as a model to develop novel ligands.70 For example, Hlasta et

studied a series of

indolin-2-yl (Table 5) and tetrahydroquinolin-2-yl imidazolines. It has been suggested that
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the ortho di-chloro substitution pattern of clonidine (43) helps to restrict the imidazoline
ring in a position that is perpendicular to the 2,6-dichlorophenyl ring.70 This conformation
is supposed to be responsible for the a2-adrenoceptor agonist activity of ~lonidine.~'
It was
shown that the cis-indoline 45 (Ki = 6.9 nM) possesses high affinity that was comparable
with clonidine. The trans-indoline 46 (Ki = 72.3 nM), which is less sterically hindered,
showed a decrease in affinity at a 2 - a d r e n o ~ e ~ t o rVarious
s . ~ ~ heteroatoms were introduced
into the side chain that was added to the indoline at the 2-position.70These additions to the
indoline resulted in high affinity for these agents at a2-a d r e n o ~ e ~ t o rRing
s . ~ ~expansion of
the indolines to, for example cis-tetrahydroquinoline 47 (Ki >10,000 nM) resulted in
elimination of affinity.70

Table 5. Observed Binding Affinities of Indolin-2-yl imidazolines at a 2 - ~ d r e n o c e ~ t o r s . ~ ~

CH,

45-46 and 48-53

~~-

45
H
46
H
48
CH3
49
CH2CH=CH2
50
CH2CH2CH2
51
CH20CH3
52
CH2SCH3
53
CH2N(i-Pr)2
clonidine

It has also been suggested that the structure of clonidine (43) has to be in a specific
conformation to interact with the receptor.71The basic nitrogen must lie at a short distance
above the plane of the aromatic ring with the plane of the imidazoline ring perpendicular to
the plane of the aromatic ring.71 This conformation prevents any resonance interaction
between the aromatic portion and the imidazoline ring.71 So in order to study this
conformation, a series of spiro-imidazolines was developed and analyzed (Table 6). The
parent compound (i.e., 54) was found to bind at azA-adrenoceptorswith high affinity (Ki =
34 nM) and at ~t~~-adrenoceptors
with decreased affinity (Ki = 275 n ~ ) . Adding
~ '
a fluoro
group at the R1 position increased the binding affinity at both a2A- and ~t~~-adrenoceptors
(55, Ki = 12 and 152 nM, respectively).71 Chloro groups in the R2 and Rq positions also
increased the affinity at both

a2,4-

and a2B-adrenoceptors (56, Ki = 3 and 95 nM,

respectively).71 Adding an electron donating group in the R1 position, a methoxy group
(i.e., 57), decreased the affinity at the a2A-adrenoceptors(Ki = 51 nM) but had a similar
affinity at ~x~~-adrenoceptors
(Ki = 99 nM) when compared to ~ 6 .A~methoxy
'
group in the
R2 position (i.e., 58) increased the affinity at azA-adrenoceptorsbut decreased the affinity
at ~x~~-adrenoceptors
(K,= 18 and 193 nM, respectively).71More analogs were studied and
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it was shown that this conformation might be one of the ways that clonidine (43) binds at
both a2A- and a2B-adrenoceptors.7 1

Table 6. Observed Binding Affinities of Irnidazolines at a2A- and a 2 ~ - ~ d r e n o c e ~ t o r s . ~ '

Oxyrnetazoline (62) is another example of an imidazoline but it shows selectivity
among the a2-adrenoceptor subtypes. Oxymetazoline (62) binds with higher affinity at
a2A-adrenoceptors(Ki = 5.6 nM) than at

a2B-

and a2c-adrenoceptors (Ki = 350 and 72 nM,
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respectively)." This agent is one of the few selective a2*-adrenoceptor agonists that has
been developed. Although oxymetazoline (62) is selective among the a2-adrenoceptor
subtypes, it also binds at a,-adrenoceptors (Ki= 29.8 n ~ ) . ~ ~

Oxyrnetazoline (62)
The substituted guanidines are a small class consisting of a couple of ligands that
bind at a2-adrenoceptors nonselectively. Two representative agonists in this class are
~ has
* been shown that
guanabenz (63, Ki = 16.7 nM) and guanfacine (64, Ki = 24.9 n ~ ) . It
the substituted guanidines also bind at another receptor population, the imidazoline
receptors.68

Guanabenz (63)

Guanfacine (64)
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An analog of the imidazolines, medetomidine (65, Ki = 25 nM), is a highly potent
nonselective a2-adrenoceptor agonist.68A series of conformationally restricted analogs of
medetomidine was developed and analyzed as possible a2-adrenoceptoragonists.72For

Medetoniidine (65)

example, tetralin 67 (Table 7) displayed about 4-fold lower affinity than 65. In this
tetralin series, the 5-methoxy analog retained affinity at a2-adrenoceptors (66, Ki = 98
n ~ ) Other
. ~ analogs
~
are shown in Table 7.72 In the 3,4-dihydronapthalene series (Table
7), a methoxy group in the 5-position decreased the affinity by more than 50-fold (72, Ki =

1420 n ~ ) A. methyl
~ ~ group (73, Ki = 3 1 nM) in the 5-position resulted in similar affinity
as medetomidine (65).72However adding methyl groups in the 5- and 7-positions resulted
in a decrease in affinity (74, Ki = 232

As seen in the 5-substituted tetralin series, a

methoxy group in the 6- or 7-position decreased affinity (75, 76, Ki = 580 and 1570 nM,
respectively).72 The 4-methylindan analog 77 (Ki = 8.8 nM) displayed enhanced affinity
relative to 65.72

Table 7. Observed Binding Affinities of Conformationally Restricted Analogs of
Medetomidine at a 2 - ~ d r e n o c e ~ t o r s . ~ ~

In a previous study, Gentili et a1.73 showed that modifying the structure of
imidazoline compounds resulted in a significant difference in their affinity at

a2-

adrenoceptors. It was found that imidazolines 78 and 79 were antagonists at

a2-

adrenoceptors and weak agonists at a,- a d r e n ~ c e ~ t o rFrom
s . ~ ~ this study, biphenyline (80)
was also developed and found to be selective for a2-adrenoceptors and also behaved as an
@-adrenoceptor agonist in in vitro assays.73Biphenyline (80) was obtained by introducing
a phenyl ring in the ortho position of the 2-[I-@henoxy)ethyl]-imidazoline

basic

structure.73 It was suggested that this phenyl group might be responsible for the agonist

Biphenyline (80)
activity seen with biphenyline

Various modifications were made to the phenyl ring

in the ortho position and resulted in a series of biphenyline analogs (Table 8).73 The
affinity and intrinsic activity were measured for these biphenyline analogs as well as
biphenyline

Biphenyline (80) was found to bind with higher affinity at

a 2 ~ -

adrenoceptors when compared to a 2 ~and
- a2c-adrenoceptors (Ki = 47, 501, and 199 nM,
respectively).73 It also behaved as an agonist at both

and azc-adrenoceptors and a

partial agonist at azB-adrenoceptors.73Therefore a major focus for this study was to modify
the phenyl group in order to develop subtype selective a2-adrenoceptor agonists. The first
approach was isosteric substitution with a pyridine or thiophene nucleus.73 The pyridine
derivatives 81 and 83 resulted in lower affinity at a2-adrenoceptorswhen compared to

Table 8. Observed Binding Affinities of Biphenyline Analogs at a2-Adrenoceptor

ia = intrinsic activity, NA = not active (ia < 0.3)

biphenyline (80) and were inactive at all three subtypes.73 However, 82 possessed higher
affinity at a2-adrenoceptors than the other pyridine derivatives and showed selectivity at
azc-adrenoceptors.73 Compound 82 behaved as an agonist at a2c-adrenoceptors and a
partial agonist at the other subtypes.73The thiophene nucleus possesses aromaticity that is
comparable to that of a phenyl ring.73Both 84 and 85 behaved as agonists at a2A- and a2cadrenoceptors and showed more selectivity in affinity for the ~ t ~ ~ - a d r e n o c e ~The
t o rnext
.~~
approach was to incorporate various substitution at the ortho, meta, and para positions of
the phenyl ring. A methyl group was added to the ortho, meta, or para position (86, 87,
and 88, respectively) and none of these compounds were active at

a2~-or

a2~-

adrenoceptors but behaved as partial agonists at a2c-adrenoceptors.73 When a hydroxy
group was added at these three positions (89, 90, and 91), the only active compound was
the m-hydroxy derivative 90 (K, = 18 nM, ia = 1.15) that behaved as a h l l agonist with
high affinity at azc-adrenoceptors.73 To further test the possible role that an electronic
effect has on binding and agonist activity, a nitro group was added at the ortho, meta, and
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para positions (92, 93, and 94, respectively).73All three nitro derivatives were inactive at

a2,4- and a 2 ~ -adrenoceptors.73 However, the m-nitro derivative 93 was the only nitro
derivative that showed any activity at a2c-adrenoceptors.73Since the meta position seemed
to be optimal for agonist activity, several other substituents were introduced at this
c

position. An amino derivative 95 possessed moderate affinity for all three a2-adrenoceptor
subtypes but behaved as a partial agonist at

a2,4-and

a 2 ~a-d r e n ~ c e ~ t o rAddition
s.~~
of a

fluoro group in the meta position, 96, showed an increase in affinity compared to
biphenyline (80) and behaved as a full agonist at a2c-adrenoceptors and as a partial agonist
at a2A-adrenoceptors.73This was the first series of a2-adrenoceptor ligands that showed
subtype selectivity for ~t~~-adrenoceptors
Currently, there are available a2-adrenoceptor agonists that bind nonselectively at
the a2-adrenoceptor subtypes. However, there are still only a limited number of agonists
that show subtype selectivity for ~ ~ ~ ~ - a d r e n o c e pversus
t o r s a2B- and a2c-adrenoceptor
subtypes. Although these agonists show subtype selectivity among the a2-adrenoceptor
subtypes, they also bind at other receptor populations (i.e., 5-HT and a,-adrenoceptors).
Still, there is no strictly subtype-selective a2A-adrenoceptor agonist that has been
developed.

There are also no subtype-selective azB-adrenoceptor agonists available.

Recently, subtype selective a2c-adrenoceptor agonists have been developed and might be
used to determine the physiological effects of a z c - a d r e n ~ c e ~ t o r sSelective
.~~
a2adrenoceptor subtype agonists can help to further understand the physiological effects of
each subtype and also to manage any disorders that are mediated by the a2-adrenoceptor
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subtypes.

There is an increasing clinical, and basic science, need for selective a2-

adrenoceptor subtype-selective agonists.

b) Antagonists

Many a2-adrenoceptor antagonists have been developed over the years. These
antagonists have been used to classify the a2-adrenoceptor subtypes via radioligand
binding studies. a2-Adrenoceptor antagonists come from a variety of chemical classes.
Some representative a2-adrenoceptor antagonists include yohimbine (39), rauwolscine
(97), imiloxan (98), and SK&F 86466 (99). Yohimbine (39), an indole alkaloid that has
been isolated from Pausinystlia yohimbe bark and Rauwolfia root, has been used in herbal
medicines for centuries.'

'0

Rauwolscine (97)

CH~

Imiloxan (98)

Yohimbine (39) is an a2-adrenoceptorantagonist that binds at the a2,-adrenoceptor
subtype (Ki = 7.5 nM), a2~-adrenoceptorsubtype (Ki = 4.6 nM), and ~t~~-adrenoceptor
subtype (Ki = 2.3 nM) with similar affinity.68 Since yohimbine (39) binds at

a2-

adrenoceptors with such high affinity, other yohimbine derivatives were examined and
characterized as a2-adrenoceptor antagonists. Rauwolscine (97) is also an alkaloid that
belongs to the same family as yohimbine, the yohimbanes.68Rauwolscine (97) binds at the
a2-adrenoceptor subtypes nonselectively: a2,-adrenoceptor subtype (Ki = 4.6 nM),

a2~-

adrenoceptor subtype (Ki = 4.7 nM), and ~t~~-adrenoceptor
subtype (Ki = 1.0 nM), and
with an affinity comparable to that of yohimbine (39).68 Several other analogs of
yohimbine, raubasine (100) and akuammingine (101), are also selective a2-adrenoceptor

antagonist^.^'

Both of these analogs have been isolated from the same sources as

Raubasine (100)

Akuammingine (101)
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yohimbine (39) and are known as h e t e r ~ ~ o h i m b i n e sRaubasine
.~~
(100) binds at all of the
a2-adrenoceptor subtypes with high affinity: ~ ~ ~ - a d r e n o c e psubtype
tor
(K, = 8.2 nM), a 2 ~ adrenoceptor subtype (Kl = 14.5 nM), and azc-adrenoceptor subtype (Ki= 5.0 JM).~'
Akuammingine (101) binds at each a2-adrenoceptors with lower affinity than yohimbine
(39): a2~-adrenoceptorsubtype (K, = 106 nM), ~x~~-adrenoceptor
subtype (K, = 116 nM),
and a2c-adrenoceptor subtype (K, = 28 n ~ ) . ~ '
Imiloxan (98) is an a2-adrenoceptor antagonist that belongs to another class, the
b e n ~ o d i o x a n sImiloxan
.~~
(98) is a benzodioxanyl N-ethylimidazole that binds selectively
at the a2B-adrenoceptorsubtype (K, = 136 nM) compared to a2A- and a2c-adrenoceptor (Ki

= 1701 and 1056 nM respectively).75 Imiloxan (98) has been used to characterize the
physiological functions of a2B-adrenoceptors, since it is the only available a 2 ~ adrenoceptor-selective antagonist. When imiloxan (98) originally was implicated as a
and
selective a2e-adrenoceptor antagonist, its binding activity was studied only at a2~a2B-adrenoceptors.76,77However, it has been shown that imiloxan (98) blocks the
antinociceptive activity of the a2-adrenoceptor agonist, ST-91 (44), whose actions are
thought to be mediated primarily through the w-adrenoceptor subtype.78 Currently, there
is great controversy for which a2-adrenoceptor subtype imiloxan (98) is truly selective:
a2B-

or a2c-adrenoceptors. Idazoxan (102), a benzodioxanyl imidazoline, is also an az-

adrenoceptor antagonist. Unlike imiloxan (98), idazoxan (102) binds nonselectively at the
a2-adrenoceptor subtypes: a2A-adrenoceptor subtype (Ki = 21 nM), azB-adrenoceptor
subtype (Ki = 43 nM), and azc-adrenoceptor subtype (Ki = 35 nM).59

Idazoxan (1 02)

'

Another class of a2-adrenoceptor antagonists are the benzazepines (Table 9).68
SK&F 86466 (99) shows moderate selectivity for a2-adrenoceptors versus a,adrenoceptors, but binds at the a2-adrenoceptor subtypes nonselectively: a2*-adrenoceptor
subtype (Ki = 9.4 nM), a2~-adrenoceptorsubtype (Ki = 16 nM), and a2c-adrenoceptor
. ~ ~
86466 (99) has been used to subclassify a2-adrenoceptor
subtype (Ki = 20 n ~ ) SK&F
physiological responses in functional assays.68 A heterofused analog, SK&F 104856 (103)
shows approximately 8-fold selectivity for the a2B-adrenoceptorsubtype (K; = 3.4 nM),
when compared to ~t~~-adrenoceptor
subtype (Ki = 24 nM) and a2c-adrenoceptor subtype
. ~ ~related 3-benzazepine derivatives have been developed; some are
(Ki= 2 1 n ~ ) Several
shown in Table 9.68

Table 9. Observed Binding Affinities of 3-Benzazepine Derivatives at a2Adrenoceptor

A well-known a2-adrenoceptor antagonist belongs to a group, the quinazolines, that
mostly behaves as a]-adrenoceptor antagonists. Quinazolines do not discriminate between
the a]-adrenoceptors but several, including prazosin (107), have been shown to bind at a2adrenoceptors. Evidence shows that prazosin (107) binds selectively at both a2B- and a2c-
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adrenoceptors with high affinity (Ki = 30.6 and 10.7 nM, respectively) when compared to
~t~~-adrenoceptors
(Ki = 302 n ~ ) . ~ ~

fi~,
Prazosin (107)
In general, a number of a2-selective antagonists have been identified, but with the
exception of imiloxan (98), few show selectivity within the a2-adrenoceptor family.
Furthermore, it is currently unknown whether imiloxan is an a 2 ~a, 2or~a2Bla2c-selective
antagonist.

c) Therapeutic Application of a*-Adrenoceptor Agents
a2-Adrenoceptor agonists and antagonists have a wide range of therapeutic
applications. a2-Adrenoceptor agonists have been used in the treatment of hypertension
for many years.' This is due to the fact that a2-adrenoceptors, which are present on blood
vessels, can mediate vasoconstriction.68 Clonidine (43), guanabenz (63), and guanfacine

(64) are still being used clinically for the treatment of hypertension.' All of these agents
also bind at imidazoline receptors and are thought to require both components, a 2 -
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adrenoceptors and imidazoline receptors, to lower and maintain blood pressure.79
However, some of the drawbacks of these antihypertensives are that they cause sedation,
bradycardia, and mental depression.79 a2-Adrenoceptors are also involved with noninsulin-dependent diabete~.~','~
Activation of a2-adrenoceptors has been shown to inhibit
the secretion of insulin from pancreatic islet

Several a2-adrenoceptor antagonists,

rauwolscine (97) and idazoxan (102), enhanced glucose-induced insulin secretion in the
Yohimbine (39) increases plasma insulin, and inhibits epinephrine-induced
hyperglycemia in mice.68979Therefore, blocking R-adrenoceptors seems to play a role in
selectively enhancing glucose-stimulated insulin secretion in this type of diabetes.79
Another possible target of a2-adrenoceptors' therapeutic applications is obesity. It
has been shown that stimulating a2-adrenoceptors causes an inhibition of lipolysis in
isolated human adipocytes. This stimulation of a2-adrenoceptors could possibly be used to
promote weight l o ~ s . ~ 'In, ~rodents,
~
SK&F 86466 (99) can block R-adrenoceptors which
then stimulates epinephrine-induced lipolysis.68~79Studies have shown that long-term
treatment with SK&F 86466 (99) results in a dose-related loss in body weight that was
independent of the amount of food i n t a l ~ e . ~Since
" ~ ~ activation of central @-adrenoceptors
results in sedative effects, a2-adrenoceptor agonists have been clinically used in
a n e ~ t h e s i a . Clonidine
~~
and other a2-adrenoceptor agonists are being used as adjuncts to
general a n e ~ t h e s i a . ~a2-Adrenoceptor
"~~
agonists, detomidine and medetomidine (65), are
being used as veterinary

anesthetic^.^^'^^

Evidence shows that pretreatment with
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medetomidine (65) reduces the requirement for using gaseous anesthetics in both rats and

The noradrenergic system inhibits nociception that is primarily mediated by a 2 adrenoceptors. Noradrenergic neurons descend from the brainstem to the spinal cord and
terminate in the dorsal horn." This descending inhibitory pathway modulates pain by
constituting a gating mechanism that controls impulse transmission in the dorsal horn."
Norepinephrine (36) plays an important role in the n~odulationof pain transmission in the
brain and spinal cord."

1.t. administered norepinephrine (36) produces antinociceptive

activity in rodenk8 Q-Adrenoceptor

agonists produce antinociception through the

activation of the noradrenergic system.''

Clonidine (43), the most studied a2-adrenoceptor

agonist, produces antinociception both in rodents and humans.' Evidence shows that
clonidine produces its analgesic activity when administered systemically, epidurally, and
intrathe~all~.'The a2-adrenoceptor's role in nociception has been studied in nociceptive
tests in rodents, especially thermal nociceptive tests. In both the hot-plate and tail-flick
tests, clonidine produces dose-dependent antinociception when given via the intravenous
(i.v.), it., or s.c. route.81These studies showed that clonidine-induced antinociception is
mediated by supraspinal and spinal a2-adrenoceptor sites. Also, ST-91 (44), an analog of
clonidine, produced antinociception in rats when administered via the i t . route.'*
Activation of a2-adrenoceptors causes hyperpolarization of neurons by opening K'
channels, which seems to share a role in the antinociception produced by a2-adrenoceptor
agonists.83 Galeotti et

showed that clonidine-induced antinociception was enhanced
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by the KATPchannel openers minoxidil, pinacidil, and diazoxide in both the hot-plate and
tail-flick tests, whereas the KATPchannel blocker gliquidone attenuated the antinociceptive
activity of clonidine (43).83 a2-Adrenoceptors seem to be involved in the antinociception
mediated by other descending inhibitory systems. 5-Methoxy-N,N-dimethyltryptamine (5MeO-DMT), a 5-HT agonist, produced a dose-dependent antinociception that was blocked
by yohimbine (39).84 This study suggested that 5-HT-induced antinociception might be
dependent on the descending noradrenergic system. In another study, Svokos et al?
showed that i.c.v. administered improgan, a histamine-2 receptor ligand, produced
antinociceptive activity in rats. When i.p. or i.t. administered yohimbine (39) was given,
yohimbine (39) attenuated the antinociceptive activity of improgan.85 However, i.c.v.
administered yohimbine (39) did not attenuate the antinociceptive activity of improgan.85
These results showed that a2-adrenoceptors play a role in antinociception induced by
histamine receptors but only the spinal az-adrenoceptors were involved. a2-Adrenoceptors
might also be involved in GABAB receptor-induced antinociception. Sabetkasai et aLg6
showed that i.p. administered baclofen, a representative GABAB agonist, produced
antinociception in mice in the tail-flick test. The antinociceptive activity of baclofen was
blocked by i.p. administered yohimbine (39).86This study further demonstrated the various
systems that induce antinociception might be influenced by the noradrenergic system
(Figure 7).

DESCENDING INHIBITION

DESCENDING FACILITATION

Figure 7. Schematic diagram of noradrenergic system modulating noci~e~tion.~
This figure is used
to show the involvement of the noradrenergic system with other neurotransmitters.

Thermal nociceptive tests were also used to further understand which

a2-

adrenoceptor subtypes might be involved in antinociception mediated by a2-adrenoceptors.
In a study by

ill an,^^ S.C.administered UK 14,304 (108), an a-adrenoceptor agonist,

produced antinociceptive activity in mice in the hot-plate test. Several a2-adrenoceptor
antagonists, both nonselective or subtype selective, were used to study a;?-adrenoceptor
subtype i n ~ o l v e m e n t .The
~ ~ nonsubtype selective a2-adrenoceptor antagonist idazoxan
(102) blocked the antinociceptive activity of LTK 14,304 ( l 0 8 ) . ~Both
~
BRL 44408 (109)

and RX 821002 (110), a2~-adrenoceptorantagonists, also blocked UK 14,304-induced
antino~ice~tion.~'
However, BRL 4 1992 (111) and ARC-239 (112) and prazosin (107),
selective

a 2 ~ - and

a2c-adrenoceptor antagonists, did not have any effect on the
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antinociceptive activity of UK 1 4 , 3 0 4 . ~This
~ study suggested that among the supraspinal
a2-adrenoceptor subtypes, only a2A-adrenoceptors are involved with antinociception
induced by a2-adrenoceptor agonists.

UK-14,304 (108)

BRL 44408 (109)

0

C N H

RX 821002 (110)

Figure 8. Subtype selective a2-adrenoceptor ligands.87

BRL 41992 (111)
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All of the previous studies in the hot-plate test showed that i.t. administered
clonidine (43) and ST-91 (44) produced dose-dependent antinociception that activated
supraspinal Q-adrenoceptor

site^.^'-^^

However, it was also shown that the it.-

administered a2-adrenoceptor agonist dexmedetomidine was inactive in the hot-plate test
but active in the tail-flick test.88This could be due to the fact that clonidine (43) and ST-91

(44) are very lipid soluble compounds.

This means that when these agents are

administered directly into the spinal cord they are absorbed rapidly into the blood and
diffused to other parts of the C N S . ~This allows these agents to activate a*-adrenoceptors
that are located in the brain. This idea was supported by the study by Ossipov et d8'that
showed that i.v. administered clonidine (43) produces antinociception in both the hot-plate
and tail-flick tests.

There has been controversy about the actual involvement of

supraspinal a2-adrenoceptors in the antinociception induced by spinally-administered a2adrenoceptor agonists. In another study, it was shown that i.t. administered clonidine (43)
still produced potent antinociceptive activity after transection of the spinal cord.8 This
suggests that although supraspinal a2-adrenoceptors could possibly contribute to
antinociception, activation of these sites might not be required to produce the maximal
antinociceptive effect of clonidine (43).
Earlier studies showed that a2-adrenoceptors have influence on the mediation of
opioid-induced antinociception. Norepinephrine (36) is a modulator of the antinociceptive
activity produced by opioid agonists in the spinal cord.*' 1.t. administered yohimbine (39)
blocks the antinociceptive activity of i.t.-administered morphine.89 This evidence further
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suggests that a2-adrenoceptors are involved in morphine-induced antinociception.
However, naloxone, an opioid antagonist, did not attenuate the antinociceptive activity of
clonidine (43).89Coadrninistration of Q-adrenoceptor agonists and opioid agonists resulted
in a greater-than-additive antinociceptive effect, or synergy.90 These agents could be
administered in lower doses than when administered separately to produce an equivalent
antinociceptive effect.90 This is important because this combination could be used
clinically in pain therapies. The morphinelclonidine synergism allows a more efficient
treatment that involves lower doses which probably was associated with lower risk of
undesired side effects. Separately, morphine and clonidine (43) are being used clinically in
the treatment of pain, including postoperative and cancer pain.90 Therefore, the morphine
Iclonidine synergism has been extensively studied in rodents using both tail-flick and hotplate tests. Systemically or spinally coadministered morphine and clonidine (43) produce a
potentiation in antinociceptive activity in several animal s t ~ d i e s . * ~Since
- ~ ' morphine
produces the development of tolerance, the synergistic effect of morphine and clonidine
(43) was studied in mice that were either acutely or chronically tolerant to morphine.90
Fairbanks and ~ i l c o x ~showed
'
that mice acutely tolerant to i.t.-administered morphine
still produce a synergistic effect when morphine and clonidine (43) were coadministered
via the i.t. route.90 Similar results were shown when the mice were chronically tolerant to
i.t.-administered morphine.90 These results showed that even though tolerance develops
from the use of morphine, coadministration of morphine and clonidine (43) could still be
an efficient therapeutic treatment of pain.
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Coadministration of clonidine (43) and morphine has been used clinically in
patients for the treatment of postoperative pain. It was shown that epidural clonidine (3
pglkg) plus morphine (0.05 mglkg) provided better postoperative analgesia than epidural
morphine alone after a gastrectomy.92 Evidence shows that the combination of these two
I

analgesics can also be used in postcesarean analgesia.93 In a recent study, it was reported
that the combination of subarachnoid morphine and clonidine (43) increased the duration
of postcesarean analgesia when compared with morphine or clonidine (43) alone.93 This
combination also reduced the opioid requirement and increased intraoperative sedation.93
As mentioned earlier, studies have shown that the a2*-adrenoceptors are involved
in antinociception. It was recently found that both a2B- and a2c-adrenoceptor subtypes
could also play a role in mediating antinociception. Prazosin, which is selective for

(32~-

and a2c-adrenoceptors, inhibited neurotransmitter release from spinal cord preparations.78
This supports the idea of possible roles for both a2B- and a2c-adrenoceptors in
antinociception.

.~~
that activation of a2B-adrenoceptors could
Sawamura et ~ 7 1 showed

mediate the antinociceptive activity of nitrous oxide, an adjunctive general anesthetic. In
this study, null mice for the a2B-adrenoceptor subtype produced a reduced or absent
analgesic response to nitrous oxide.94
a2-Adrenoceptor agonists have been classified as being potent analgesics.
Although a2-adrenoceptor agonists are being used therapeutically as analgesics, they still
produce the undesired side effects of sedation, hypotension, and bradycardia. The use of
a2-adrenoceptor agonists in combination with other clinically known analgesics has been
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studied over the years. This allows a2-adrenoceptoragonists to be used therapeutically but
in lower doses than those that prevent the development of undesired side effects. It has
been shown that the a2*-adrenoceptor subtype is responsible for the hypotensive, sedative,
and bradycardic actions associated with a2-adrenoceptor agonists.78 The development of
a2-adrenoceptor agonists that are selective for a 2 ~
and/or
- a2c-adrenoceptors has become a
major interest in the field of analgesia.

D. Behavioral Tests for Nociception
Measuring pain and analgesia in animals can be quite difficult. This is mainly
because pain itself consists of a multiplicity of sensory entities.95Also, the term "pain" is
poorly defined when related to animals and their behavior.95 Pain is a subjective and
personal psychological experience that cannot be measured directly in animals since an
animal cannot describe how it feels.95Therefore the term "pain" is usually avoided when
describing the study of nociception in animal models,95 rather, the term "antinociception"
is used. The antinociceptive effect of a test compound can be measured in animal models,
and many factors can influence the outcome of the measurements in all animal models of
n o ~ i c e ~ t i o Different
n . ~ ~ species and strain of animals can have a major affect on the test
results and is one of the more obvious factors.95Another factor is that the time of day that
the test is being conducted can produce a variation in results.95 Skin temperature of the
stimulated area can influence the response to heat stimulus and is a factor that is important
in thermal nociceptive test^.^^,^^ Nociceptive tests can be useful when they are carefully
performed. In nociceptive tests, various types of stimuli can be used. Specifically, in
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thermal nociceptive tests, heat stimulus is used to induce a response to nociception in
rodents.95 In thermal nociceptive tests, the stimulatory response is fixed and a standard
response is defined.95 The duration of the heat stimulus, when the nociceptive response
occurs, is measured, and thermal nociceptive tests mainly focus on the threshold of the
heat stimulus required to induce a specific response.95
Two well-known thermal nociceptive tests, tail-flick and hot-plate tests, have been
used extensively in studying nociception and antinociception in rodents. Both the tail-flick
and hot-plate tests were first described more than 60 years ago.95797The tail-flick test was
developed by D'Amour and

and is used both in rats and mice. In the tail-flick

test, radiant heat is focused on the rodent's tail and the time is measured for how long it
takes for the animal to flick its tail away from the beam.95 This measurement is known as
tail-flick latency, which is a measure of the sensitivity of the animal to heat stimulus. A
maximal cut-off time is employed to prevent damage to the tail tissue.95When an analgesic
is administered to an animal, the agent can prolong the tail-flick latency. Spinal receptor
sites are primarily involved in producing the nociceptive response seen in the tail-flick
This idea was studied by transecting the spinal cord above the lumbar level."
From such studies, it was shown that transection does not block the tail-flick response.95
The tail-flick test is very reliable for studying nociception in rodents. However, there is
one factor that can possibly result in a variation in data. The skin temperature of the
animal is negatively correlated with tail-flick

The tail-flick response is induced

when the temperature at the nociceptors in the skin reach a critical

The tail-flick

latency depends strongly on the initial temperature of the skin which is influenced by local
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blood f l o ~ . SO
~ ~certain
, ~ ~ manipulations that affect thermoregulation could cause
variation in the results; these include lesions of the descending noradrenergic or
serotonergic systems, transection of the spinal cord, administration of serotonin or
norepinephrine receptor agonists or antagonists, and stress and handling of the animals.96
Skin temperature is critical because reduction in the tail skin temperature

can be

interpreted as a n t i n o ~ i c e ~ t i o nThis
. ~ ~ problem can be avoided by recording the tail skin
temperature and making corrections to the tail-flick latency accordingly.95 In contrast,
Lichtman et a1. '0° showed that tail-flick latency is not influenced by the skin temperature
of the rodent. Thus there is some controversy whether skin temperature actually causes a
variation in results from tail-flick tests.
The hot-plate test was developed by Woolfe and ~ a c ~ o n a l d " and
'
is also
extensively used in studying nociception in rodents. When first described, the hot-plate
test measured the nociceptive response of rodents placed on a hot-plate apparatus at
temperatures varying from 55 to 70 " c . ~ 97
~ ' The hot-plate test was later modified and a
constant temperature of 55 "C is the temperature that is consistently used today.95,97 The
latency to a variety of behavioral responses, including jumping, kicking, shaking of the
foot, holding a foot tightly against the body, and licking the forepaw andlor the hindpaw, is
used to measure the sensitivity to pain in rodents.97 Usually, hindpaw licking latency is
used as the end-point.97 A maximal cut-off time is also employed in the hot-plate test. The
hot-plate test focuses on the supraspinal receptors that are involved in mediating
. ~ ~problem seen in the hot-plate test is that mild
nociception and a n t i n o c i ~ e ~ t i o nOne
analgesics possess no, or weak, antinociceptive activity at a constant temperature of 55
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" c . ~Therefore,
~
the increasing temperature hot-plate test was developed to solve this
problem. 95,97,102 In this test, the temperature of the plate is set below the pain threshold and
is gradually increased until the animal makes a response.95 The temperature at which the
response occurs is then recorded as the nociceptive endpoint.95 The increasing temperature
hot-plate test can be used with a conventional hot-plate which is initially set at 42- 43 "C
and the cut-off temperature is 50- 52 " c . ~ ' , ~This
~ test is more sensitive than the constant
temperature hot-plate

For example, earlier studies showed that the mild analgesics

acetylsalicylic acid and paracetamol showed antinociceptive activity at 50 "C but not at 55
or 59 "C.95,97,102
Thermal nociceptive tests are the most commonly used nociceptive tests in rodents.
Since the development of both the tail-flick and hot-plate tests, there have been
modifications made to each test to enhance the reliability of the results collected. The
results from both of these tests might be affected by the skin temperature of the animal.
However, the tail-flick test may be more susceptible to this problem than the hot-plate test.
Use of the increasing temperature hot-plate test prevents the possible influence that skin
temperature might have. In the case of the tail-flick test, this situation can be prevented by
measuring the skin temperature of the animal before the test. However, this has been
refuted.'OO Both thermal nociceptive tests have been extremely reliable in studying
nociception and antinociception in rodents.

111. Specific Aims and Rationale

It was previously shown by Dukat et al.30 that MD-354 (21) binds at 5-HT3
receptors with high affinity (K; = 35 nM). Additional binding studies showed that this
compound also binds at az-adrenoceptors with high affinity.'03 MD-354 (21) binds

(K;
- = 825 nM) and
selectively at a2B-adrenoceptors (Ki = 25 nM) when compared to a 2 ~
(Ki = 140 nNI).lo3As such, it might be viewed as the first example of a
~t~~-adrenoceptors
rather selective 5-HT3/a2B-adrenoceptor ligand.

Because 5-HT3 receptors and a 2 ~ -

adrenoceptors both have been implicated as playing a role in antinociception, MD-354 (21)
might represent a novel, dual-mechanism type of analgesic agent. MD-354 (21) was first
studied in the mouse tail-flick test. The antinociceptive activity of MD-354 (21) was
compared with that of clonidine (43) as positive control.Io3It was found that 1.0 mglkg of
clonidine (43) produced 76% of the maximal possible effect (MPE) when administered via
the S.C.route 20 min prior to the test.Io3Other doses were evaluated and it was shown that
clonidine (43) produced a dose-dependent antinociceptive effect (Figure 9).Io3

Saline
Clonidine Dose (mglkg)

Figure 9. Antinociceptive actions of clonidine following S.C.administration in the mouse tail-flick
assay. Asterisks denote significant differences compared to control group (i.e., saline); *P< 0.01
and **P< 0.001. I o 3

Subcutaneous administration of MD-354 (21) at doses ranging from 1.0 to 30
mglkg did not produce an antinociceptive effect when administered 45 min prior to testing
(Figure 10). O3 Results were not different using various other pretreatment times. MD-354
(21) was also examined as a possible antagonist of clonidine-induced antinoci~eption.'~~
When administered 45 min prior to testing, doses of 1.0, 3.0, and 10 mgkg of MD-354 did
not antagonize the antinociceptive activity of the ED50 dose of clonidine (43) administered
20 min prior to testing.lo3 Interestingly, a combination of the EDsodose of clonidine (43,

MPE = 59%) and a dose of 10 mgkg of MD-354 (21, MPE = 8%) was found to enhance
antinociception in

It was also shown that an inactive dose of 0.25 mglkg of

clonidine (43, W E = 13%) in combination with MD-354 doses ranging from 1.0 to 30
mgkg dose-dependently enhanced the antinociceptive effect in what appears to be a bellshaped manner. (Figure 11).'03

MD-354 Dose (mgtkg)

Figure 10. Effect of MD-354 doses administered 45 rnin prior to testing in the tail-flick assay as
compared to saline contr01.'~'

MD-354 Dose (mglkg) + 0.25 mglkg of clonidine

Figure 11. Potentiation of the antinociceptive actions of clonidine (0.25 mglkg) by MD-354 in
the tail-flick assay. Asterisks denote significant differences compared to control group; *P< 0.05
and **PC 0.01.Io3
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Mechanistic studies were conducted to determine the mechanism behind the
potentiating effect of clonidine antinociception by MD-354 in the mouse tail-flick test.'03
Pretreatment with the putative azB-adrenoceptorantagonist imiloxan (6.0 and 10 mglkg
i.p.) and the 5-HT3receptor antagonist zacopride (0.5 and 1.0 mglkg i.p.) failed to attenuate
the potentiation of clonidine antinociception (0.25 mglkg s.c.) by MD-354 (21, 6.0 mglkg
s.c.).'03 These results suggest that neither a2B-adrenoceptorsnor 5-HT3 receptors play a
role in the potentiating effect of MD-354 (21). Since it is still controversial to which
subtype of a2-adrenoceptors imiloxan binds, neither

a2B-

nor a2c-adrenoceptors can be

ruled out as playing a role in the potentiating effect by MD-354 (21). As previously
mentioned, clonidine potentiates the antinociceptive effects of morphine. Since MD-354
(21) enhances clonidine antinociception, the effect of MD-354 (21) on morphine
antinociception was evaluated in the mouse tail-flick assay.'03 In a combination study,
MD-354 (21) did not enhance the antinociceptive action of morphine.lo3
The purpose of the present studies was to further examine MD-354 (21) in a
different pain model (i.e., the hot-plate assay), and to further investigate its potential
mechanism(s) of action accounting for its potentiating effect on clonidine antinociception
(in both the tail-flick and hot-plate assay). MD-354 (21) will be studied in the mouse hotplate assay so that the activity in both thermal tests can be compared. Using the hot-plate
assay will help further understand the mechanism of potentiation of clonidine (43) by MD354 (21). If MD-354 (21) is active by itself or in combination with clonidine (43) in the
hot-plate assay, it would suggest that MD-354 (21) could possibly cross the blood-brain
barrier and bind at supraspinal 5-HT3 andlor a2B-adrenoceptors. This will show that the

potentiating effect by MD-354 (21) works via both spinal and supraspinal receptor sites.
Then, mechanistic studies will be conducted to determine which receptor(s) (i.e.,

a2~-

adrenoceptors andlor 5-HT3 receptors) are involved in this activity. If MD-354 (21) is
inactive and does not potentiate clonidine-induced antinociception in the hot-plate assay,
that could mean that MD-354 (21) is not lipophilic enough to cross the blood-brain barrier
and may not reach the supraspinal receptors. MD-354 (21) is not a very lipophilic agent
~ suggests that MD-354
and has an experimentally determined Log P value of - 0 . 6 4 . ~This
(21) might have difficulty penetrating the blood-brain barrier.

To study this, the

carbarnate derivative of MD-354 (21), 113, will be synthesized and evaluated in both
thermal assays.

Addition of the carbarnate moiety might sufficiently potentiate the

lipophilicity of 21 so that it can penetrate the blood-brain barrier. In theory, carbamate 113
should act as a prodrug and be hydrolyzed to MD-354 (21) in the brain. If 113 does reach
the supraspinal receptors, then 113 should be hydrolyzed to MD-354 (21) and possess
antinociceptive activity in the hot-plate assay. Compound 113 will also be evaluated in
combination with clonidine in both thermal assays and these results will be used to
compare with the actions of MD-354 (21). If 113 produces a similar dose-response curve
as MD-354 (21) in the mouse tail-flick assay, this would suggest that 113 is hydrolyzed to
MD-354 and is interacting in the same manner.

Next, mechanistic studies will be conducted to determine which pathway, 5-HT3
and/or ~ ~ ~ ~ - a d r e n o c e pist oresponsible
r,
for potentiation of the clonidine effect. A related
analog 3,4,5-trichlorophenylguanidine,29, with a different binding profile will also be
examined. Compound 29 binds with higher affinity than MD-354 (21) at 5-HT3 receptors

(Ki = 0.7 nM) but with an affinity similar to that of MD-354 at the azB-adrenoceptors(Ki =
30 nM). However, unlike MD-354 (21), 29 does not show subtype selectivity (a2*, azc; Ki

= 32 and 30 nM, respectively). First, 29 will be evaluated in the mouse tail-flick assay. If
the potentiating effect is due to 5-HT3 receptors, then 29 should be more potent than MD354 in potentiating clonidine (43). Because 29 possesses 50 times the affinity of MD-354
at 5-HT3 receptors, it should have a comparatively greater potency relative to MD-354 (21)
in its potentiating effect if the effect is primarily related to a 5-HT3receptor mechanism. If
the potentiating effect is via the a2B-adrenoceptors,then 29 should have similar potency as
MD-354. Antagonist studies also will be conducted to determine the involvement of 5HT3 and/or ~x~~-adrenoceptors.
The 5-HT3 antagonist tropisetron (33), the putative

a2B-

adrenoceptor antagonist imiloxan (98), and the a2-nonselective adrenoceptor antagonist
yohimbine (39) will be used to attenuate the potentiating effect of 29. Compound 29 will
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also be evaluated in the hot-plate assay to see if this compound reaches the supraspinal
receptors and the results will be compared with those from MD-354 (21). Combination
studies of 29 and morphine will be conducted to determine if 29 potentiates the
antinociceptive effects of morphine.

Since clonidine (43) has been shown to produce
i

sedation via a2-adrenoceptors, 29 will be evaluated in the spontaneous activity assay in
mice. If 29 produces sedative effects (as indicated by a decrease in locomotor activity),
then its potentiating effect could possibly be due to induced sedation. If 29 does not
produce sedation, this would further suggest that it possesses actions which selectively
potentiate the antinociceptive effect of clonidine (43).
Another phenylguanidine, 3-methoxyphenylguanidine, 26, will be synthesized and
examined for possible antinociceptive actions in the mouse tail-flick assay. The rationale
for its evaluation is that it lacks significant affinity for 5-HT3 receptors (Ki = 1600 n ~ ) , ~ '
but binds nearly equally well at the three different subpopulations of a2-adrenoceptors
(a2*, a2J3, a2c; Ki = 177, 152, and 135 nM, respectively). Furthermore, it binds with only
several-fold lower affinity than 29 at each of the a2-adrenoceptor subtypes. This analog
will help determine whether 5-HT3 receptors play a significant role in the potentiating
effect seen with MD-354 (21). A constrained analog of MD-354 (i.e., 114) will also be
synthesized and examined in antinociceptive assays. The constrained analog of MD-354,
114, can be used to hrther understand which conformation of MD-354 is more important
for binding at 5-HT3 and a2~-adrenoceptors.Compound 31 has been previously prepared
as a conformationally-constrained analog of M D - 3 ~ 4 .Compound
~~
114 represents a
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conformationally-constrained rotamer of 31. If it possesses high affinity similar to MD354, then this analog will also be evaluated in both .thermal assays.

The overall focus of the studies that have been proposed is to determine the
mechanism of the potentiating effect of clonidine-induced antinociception by MD-354 and
MD-354-type compounds in the mouse tail-flick assay.

IV. Results and Discussion

A. Synthesis

a) N-(3-Chloropheny1)guanidine Nitrate (MD-354; 21)
The method of Kreutzberger and

an taw^''^ (Scheme 1) was used to prepare N-(3-

chloropheny1)guanidine nitrate (21). Cyanamide, 3-chloroaniline (115), and concentrated
HCl in absolute EtOH were allowed to stir with heating at reflux for 48 h. Thin-layer
chromatograpy (TLC) was used to monitor the status of the reaction, and after 48 h the
reaction gave a single separate spot from the starting material. The EtOH was removed
under reduced pressure and the resulting brown oil was kept at 0 OC overnight. Water and
an excess of ammonium nitrate were added to give a white precipitate which was collected
by filtration. The white precipitate was recrystallized from hot water and a drop of MeOH
to give 21 as a white powder.

115

21

Scheme 1. a. NH2CN, EtOH, concentrated HC1, reflux; b. NH4N03,H20.

b) Carbamate analog of MD-354,113
Several procedures were used in attempts to synthesize the carbarnate analog of
MD-354. The procedure of Goetz and zeeh'05 (Scheme 2) was first used. Cyanamide in
H20, methyl chloroformate, and 50% NaOH were combined and the pH was maintained
/

between 7 and 8. An exothermic reaction was supposed to increase the temperature to
between 40 and 45 OC with regulation by cooling. However, the reaction temperature
barely reached 40 "C and when it did, the temperature dropped quickly. The reaction was
to be stirred for an additional hour at 50 OC, then freshly distilled aniline 115 was added.
Concentrated HC1 was added until a pH of about 3 to 3.5 and the reaction mixture was
heated at reflux for 45 min. However, the reported precipitate did not form, but a sticky
substance was obtained that was dried under vacuum. The melting point of the unidentified

Scheme 2. a. H20, 50% NaOH in H20; b. concentrated HC1, reflux
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crude product (78-80 "C) did not correspond to the literature melting point of 128-129 "C.
The product of this reaction was never identified.
The procedure of ~hasanov'" (Scheme 3) was also applied in an attempt to
synthesize the desired product using calcium cyanamide and methyl chloroformate. The
_
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-

-
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reaction mixture was heated and the temperature was supposed to be maintained between
40 and 50 "C for 1 h.

After 1 h, the reaction mixture was filtered and 3-chloroaniline

(115) was added to the filtrate. Concentrated HCl was added to the filtrate until the pH
was adjusted to 3 and the reaction was heated at reflux for 45 min. The desired product
was reported as a white precipitate, but the product that was collected was an oily residue.
Although the product was homogeneous to TLC, the 'H NMR spectrum showed that the
oily residue was not the desired product. The identity of the product was not pursued (but
-

-

-

-

-

-

-

see below discussion).

Scheme 3. a. H20, 40 to 50 "C; b. concentrated HC1, reflux
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In yet another procedure (Scheme 4), a different approach was used to synthesize
the carbamate. Methyl chloroformate in dry THF was added to a solution of the free base
of 21 and triethylamine in dry THF at 0 OC under nitrogen. The reaction mixture was
allowed to stir at 0 OC for 30 min and then at room temperature for 16 h. After 16 h, the
precipitate was removed by filtration, and the THF was removed under reduced pressure to
give a tan powder. The tan powder was recrystallized from hot EtOH, and white crystals
were collected by filtration. 'H NMR spectral analysis indicated that the product was not
the desired carbamate, but rather the bis-carbamate analog of MD-354, 116. This
conclusion was supported by elemental microanalysis.

21 (free base)

Scheme 4. a. THF, trie-thylamine,0 "C, N 2 , 30 min; b. room temperature, 16 h.
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Thin-layer chromatographic analysis of the above reaction mixture indicated the
formation of a second, minor product that was suspected to be the desired product. The
above procedure was attempted again but the starting material was dissolved in a larger
amount of THF. It was hoped that this high-dilution technique would minimize formation
of the bis-carbamate. Under these conditions, TLC analysis showed that there was still a
small amount of starting material plus two products. The three were separated using
column chromatography. Carbamate 113 was eventually obtained in low yield as a white
powder.
Due to the low yield of the previous reaction, another attempt was made to use the
procedure of IChasanovlo6to synthesize the carbamate analog of MD-354 (Scheme 3). By
using an addition funnel, calcium cyanamide in H 2 0 was added slowly in a dropwise
manner to methyl chloroformate. The reaction temperature was maintained at around 40
"C using a hot water bath and was cooled with an ice bath if the temperature exceeded 45
"C. The reaction mixture was allowed to stir for 20 min and the precipitate was removed
by filtration; 3-chloroaniline hydrochloride was added to the filtrate. Several drops of
concentrated HC1 were added to achieve a pH of 3. The reaction mixture was heated at
reflux for 30 min rather than 45 min. The reaction produced a brown oil which was kept at

0 "C overnight. The oil obtained was dried under vacuum to yield a solid that was
recrystallized from hot H 2 0 and a few drops of EtOH. The product was dried using a
lyophilizer to give 113 as a white powder in low yield. The 'H NMR spectrum of the
product was consistent for the carbamate hydrochloride. The product isolated from this
reaction was also consistent with the product from the above reaction as determined by
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comparison of 'H NMR spectra. The free base, but not the salt, of 113 has been previously
reported. 105,106

c) N-(3-Methoxypheny1)guanidineNitrate (26).

The method of Kreutzberger and

an taw^''^ was used to prepare N-(3-methoxypheny1)-

guanidine nitrate (26) (Scheme 5). Cyanamide, m-anisidine (117), and concentrated HC1 in
absolute EtOH were allowed to stir while heating at reflux for 24 h.

Thin-layer

chromatograpy was used to monitor the status of the reaction and after 24 h the reaction
gave a single spot distinct from the starting material. The solvent was removed under
reduced pressure and half of the resulting brown oil was used to make the salt form of the
desired product. Water and an excess of ammonium nitrate were added to give a white
precipitate which was collected by filtration. The white precipitate was recrystallized from
hot H 2 0 and a drop of MeOH to give 26 as a white powder.

HN

I

A,

NH, HNO,

Scheme 5. a. NH2CN, EtOH, concentrated HCl, reflux; b NH4N03,H20
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d) A conformationally-constrained analog of MD-354, 114
The method of stadler'07 (Scheme 6) was used to synthesize 114, a constrained
analog of MD-354 (21). 2-Chloro-6-nitrotoluene (118), N-bromosuccinimide, and benzoyl

Scheme 6. a. CC14, 250-Watt bulb, reflux; b DMF, reflux; c. HZNNHZ,MeOH, reflux; d.
Raney Nickel, EtOH, HZ;e. CNBr, EtOH, reflux; f. HBr, ether.
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peroxide in carbon tetrachloride (CC14) under a 250-Watt light bulb were heated at reflux
for 26 h. The reaction mixture was filtered and the solvent was removed under reduced
pressure. TLC analysis showed that there was still a small amount of starting material plus
one product. The two were sdparated using, column chromatography. The yellow powder
was collected and recrystallized from EtOH to give 119 as yellow crystals. Compound 119
and potassium phthalamide in DMF were allowed to stir at room temperature for 2 h. The
reaction mixture was cooled to room temperature, CHC13 was added and the mixture was
poured on to H20/ice. The CHC13 portion was washed with 0.2 N NaOH, brine and dried
with Na2S04. Solvent was removed under reduced pressure to give 120 as yellow crystals.
Compound 120 and hydrazine hydrate in MeOH were heated at reflux for 3 h. Water was
added to the reaction mixture and the MeOH then removed under reduced pressure. The
solution was acidified with concentrated HC1 and heated at reflux for 1 h. The precipitate
was collected by filtration. A solution of 3 N NaOH was added to the filtrate to maintain a
pH = 9 and extracted with Et20 and brine. The Et20 extract was dried with Na2S04 and the
solvent was removed under reduced pressure. TLC analysis showed that there was one
product and one contaminant. The two were separated using Kugelrohr distillation to give
121 as a yellow oil. Compound 121 and Raney nickel in EtOH were placed on a Parr

hydrogenator for 4 h. TLC analysis showed that two products were present. The Raney
nickel was removed by filtration and washed with MeOH. The filtrates were combined
and solvent was removed under reduced pressure. The crude product was dissolved in
Et20, the solution was washed with H 2 0 and brine, and dried with Na2S04. The product
was converted to its HC1 salt and recrystallized to give 122 HCl as a yellow powder. The
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free base of 122 and cyanogen bromide in EtOH were heated at reflux for 1 h to provide
the desired target 114.
In its protonated form, compound 114 could possibly exist as one of three
tautomers (Figure 12). That is, any one of the three nitrogen atoms can be protonated. The
desired product (structure A, Figure 12) is that with the double bond located at the nitrogen
attached to the phenyl ring. The tautomeric identity of the product was verified by several
different means. First, the 'H NMR spectrum of the free base of 114 was compared with
the 'H NMR spectrum of the free base of the product reported in the literature.I0' In the
literature, it was reported that the NH and NH2 of 114 (free base) gave a broad signal at 4.7
pprn. However, the 'H NMR spectrum of the free base of 114 prepared here did not show

Figure 12. Compound 114 can exist as one of three tautomers.

the signal for the two amines at 4.7 ppm. This difference in 'H NMR spectra could be
because different 'H NMR spectrometers were used. This could also occur because the
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spectrum was run in deuterated DMSO, and if H20 is present in the DMSO the signal for
the amines can exchange.
The predicted 'H NMR spectra of the three protonated tautomers (using the
program ChemDraw) were compared to that of 114. The major difference among the three
tautomers was that the methylene signal appeared at different shifts. For tautomer A, the
methylene proton signal is predicted to be at 4.5 ppm whereas for tautomer B it is at 3.91
ppm, and for tautomer C at 2.6 ppm. This difference helped to determine which of the
three tautomers was actually obtained. That is, the actual signal for the methylene protons
of 114 was a singlet at 4.5 ppm. Another source used was the 'H NMR spectrum of a
similar, previously reported compound, 123.'08 Compound 123 is similar to tautomer A
except that it does not possess the chloro group on the phenyl ring. When comparing the

123
two 'H NMR spectra, the methylene signals are identical and show singlets at exactly 4.5
ppm. The evidence suggests that 114 is the desired tautomer (i.e., tautomer A as shown in
Figure 12).

B. Behavioral Studies
1. Results
1.1. MD-354 (21)

1.1.1. Hot-plate assay

i

The antinociceptive activity of MD-354 (21) was compared with that of clonidine
(43) in the hot-plate assay. When administered via the S.C. route 20 min prior to testing, 2

mglkg of clonidine produced 80% of the maximal possible effect (MPE, Figure 13).
Lower doses of clonidine produced less antinociception (Figure 13). In the hot-plate assay,

Saline

0.25

0.5

1

Clonidine Dose (mgtkg)
Figure 13. Antinociceptive actions (f S.E.M.) of subcutaneous clonidine in the hot-plate assay (n
= 5-8 miceltreatment). Asterisks denote significant differences compared to control group; *P<

0.001; one-way ANOVA followed by Newman-Keuls post hoc test.
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the potency of clonidine was determined (EDSo= 0.8 mglkg; 95% CL = 0.6-1.1 mglkg).
For comparison, in the tail-flick assay, EDso = 0.51 mg/kg.lo3 As seen in the tail-flick
assay, MD-354 failed to produce statistically significant antinociceptive activity in the hotplate assay (Figure 14). MD-354 produced 8-26% MPE at doses of 3, 10, and 30 mgkg
I

when administered from 10 to 90 min prior to the test. MD-354 at 30 mglkg produced a
slight, but not statistically significant time-dependent effect which diminished after the 45min pretreatment time (Figure 14).

MD-354 Dose (mgtkg):
Time (min):

3
20

10
20

10
45

30

30

30

30

10

20

45

90

Figure 14. Effect (fS.E.M.) of subcutaneous MD-354 doses administered 20 to 90 min prior to

examination in the hot-plate assay (n = 6-16 miceltreatment) as compared to saline control (8 f 2%
MPE).

1.1.2. Combination studies
In the hot-plate assay, MD-354 (21) was evaluated in combination with clonidine.
Unlike in the tail-flick assay,'03 MD-354 did not potentiate the antinociceptive activity of
clonidine. Instead, a dose of 30 mglkg of MD-354 (MPE = 11%) slightly antagonized the
antinociceptive activity of clonidine (doses 0.8 and 2.0 mglkg, 40% and 80% MPE; Figure
15). However, this slight antagonist effect was not statistically significant. In contrast, a

Clonidine MD-354 MD-354
0.8 mglkg 30 mglkg 30 mg/kg
+Clonidine
0.8 mg/kg

Clonidine MD-354
2 mglkg 30 mglkg
+Clonidine
2 mglkg

Figure 15. Effect (+ S.E.M.) of subcutaneous MD-354 (30 mglkg) administered in combination

with clonidine (0.8 and 2.0 m a g ; s.c.) in the hot-plate assay (n = 5-14 miceltreatment).

dose of 0.25 mglkg of clonidine (25% MPE) in combination with doses (10 and 30 mglkg,
10% and 11% W E , respectively) of MD-354 slightly elevated the antinociceptive activity

(NIPE = 33% and 32%, respectively; Figure 16). This slight elevation was not statistically
significant.

Clonidine MD-354 MD-354 MD-354
0.25 mglkg 10 mglkg 10 mgkg 30 mglkg
+Clonidine
0.25 mglkg

MD-354
30 mglkg
+Clonidine
0.25 mglkg

Figure 16. Effect (+ S.E.M.) of subcutaneous MD-354 doses administered in combination with

subcutaneous clonidine (0.25 mglkg) in the hot-plate assay (n = 5-26 miceltreatment).

1.1.3. MorphineMD-354 combination studies
Because clonidine has been shown to potentiate the antinociceptive actions of
morphine (see section I1 C), the effect of a morphine1MD-354 combination was examined.
Morphine (10 mgkg) produced 95% MPE (Figure 17) when administered via the S.C. route
30 min prior to the test. The potency of morphine was determined (EDSo= 2 mg/kg; 95%

CL = 1.2-3.2 mglkg) and found to be consistent with that previously reported in the
literature.'09 In a combination study, doses of 6, 10, and 30 mglkg of MD-354 did not
potentiate the antinociceptive activity of 1 mg/kg (29% MPE) of morphine (Figure 18).
When a dose of 3 mglkg of morphine (66% MPE) was administered in combination with
MD-354, there was no significant increase in the antinociceptive activity (Figure 19).

Saline

1

3

5

10

Morphine Dose (mglkg)

Figure 17. Antinociceptive actions (k S.E.M.) of subcutaneous morphine in the tail-flick assay (n

= 5-8 miceltreatment). Asterisks denote significant differences compared to control group; *P<
0.05, **P<0.01, and ***P<0.001; one-way ANOVA followed by Newman-Keuls post hoc test.

Morphine 21 Morphine 21
Morphine 21
Morphine
I mg/kg 6 mglkg 1 mg/kg 10 mglkg 1 mg/kg 30 mg/kg 1 mg/kg
+ 21
+ 21
+ 21

6 mg/kg

10 mdkg

30 mglkg

Figure 18. Effect (+ S.E.M) of subcutaneous MD-354 (21) doses administered alone and in

combination with subcutaneous morphine (1 mglkg) in the tail-flick assay (n = 5-11
miceltreatment).

Morphine MD-354
3mglkg

Figure 19.

10mg/kg

MD-354 MD-354

MD-354
lOmg/kg 30mgIkg 30mgIkg

+Morphine
+Morphine
3 mg/kg
3mgk
Effect (f S.E.M) of subcutaneous MD-354 doses administered alone and in

combination with subcutaneous morphine (3 mgkg) in the tail-flick assay (n = 5-11
miceltreatment).

1.2. N-(3,4,5-Trichlorophenyl)guanidine (29)
1.2.1. Tail-flick and hot-plate assays
The antinociceptive activity of 29 was compared with that of MD-354 (21).
Compound 29 generally produced <30% MPE at doses 0.003, 0.03, 0.3, 1.0, 3.0, 6.0, 10,
and 30 mglkg when administered 45 min prior to evaluation in the mouse tail-flick assay
(Figure 20). In the mouse hot-plate assay, 29 produced 4 0 % MPE at doses of 0.3, 1.0,
and 3.0 mglkg when administered 45 min prior to testing (Figure 21).

Compound 29 Dose (mg/kg)
Figure 20. Effect (+ S.E.M.) of subcutaneous compound 29 doses administered 45 min prior to

examination in the tail-flick assay ( n = 6-16 rniceltreatment) as compared to saline control (6 f 4%
MPE).

Compound 29 Dose (mg/kg)
Figure 21. Effect (fS.E.M.) of subcutaneous compound 29 doses administered 45 min prior to

examination in the hot-plate assay ( n = 6-16 mice/treatment) as compared to saline control (8 f 2%
MPE).

1.2.2. Combination studies
Compound 29 was evaluated in both the tail-flick and hot-plate assays in
combination with clonidine (43). In the tail-flick assay, a combination of the EDsodose of
clonidine (0.5 mglkg, MPE = 61%) and an inactive dose of 29 (0.3 mglkg, MPE = 13%)
1

potentiated the antinociceptive action of clonidine (MPE = 94%, Figure 22). However, 29
did not appear to potentiate the antinociceptive action of a very low (i.e., 0.1 mglkg) dose
of clonidine (Figure 22). But, an inactive dose of clonidine (0.25 mglkg, MPE = 13%) in

Clonidine 29
29
Clonidine 29
0.1 mg/kg 0.3 mg/kg 0.3 mg/kg
0.5 mglkg 0.3 mg/kg
+Clonidine
+Clonidine
0.1 mg/kg
0.5 mg/kg

Figure 22. Effect (*S.E.M.) of subcutaneous compound 29 (0.3 mg/kg) administered alone and in
combination with subcutaneous clonidine (0.1 and 0.5 mg/kg) in the tail-flick assay (n = 8
miceltreatment). Asterisks denote significant differences compared to clonidine control; *P<0.05;
one-way ANOVA followed by Newman-Keuls post hoc test.

combination with inactive doses (0.003, 0.03, 0.3, 1.0, 3.0, 6.0, 10, and 30 mgkg) of 29
produced increases in antinociceptive activity (43-84% MPE; Figure 23).

The

combination of clonidine (0.25 mgkg) and a dose of 0.03 mgkg of 29 (MPE = 4%) gave
the greatest potentiating effect of the antinociceptive activity of clonidine (MPE = 84%;
6

Figure 23). The effect appeared to be biphasic. After an initial increase in antinociception,
the effect was diminished at 3 mgkg of 29, and was then increased at 10 mgkg of 29
(Figure 23).

Clonidine 0.003 0.03
0.25 mgtkg

0.3

1

3

6

10

30

Compound 29 Dose (mglkg)
+ Clonidine 0.25 mgkg
Figure 23. Potentiation of the antinociceptive actions (f S.E.M.) of subcutaneous clonidine (0.25

mglkg) by subcutaneous compound 29 in the tail-flick assay (n = 8-9 miceltreatment). Asterisks
denote significant differences compared to clonidine control; *P<0.05 and **P<0.01; one-way

ANOVA followed by Newrnan-Keuls post hoc test.

In the hot-plate assay, a dose of 0.3 mgkg of 29 (MPE = 9%) significantly
potentiated the effect of the ED5()dose (0.8 mglkg, 40% MPE) of clonidine (combination:
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69% MPE, Figure 24). In contrast, a 0.3 mglkg dose of 29 in combination with lower
doses of clonidine (0.5 and 0.25 mgkg, 38% and 25% MPE; respectively) did not affect
the antinociceptive effect (MPE = 34% and 15%; Figure 24).

Clonidine Clonidine Clonidine Clonidine Clonidine Clonidine
0.25 mg/kg 0.25 mg/kg 0.5 mg/kg 0.5 mglkg 0.8 mg/kg 0.8 mg/kg

+ 29
0.3 mglkg

+ 29
0.3 mglkg

+ 29
0.3 mglkg

Figure 24. Effect (k S.E.M.) of 29 (0.3 mglkg, s.c.) administered in combination with clonidine

(0.25, 0.5, and 0.8 mglkg, s.c.) in the hot-plate assay (n = 8-9 mice/treatment). Asterisks denote
significant differences compared to clonidine control; *P<0.05; one-way ANOVA followed by
Newman-Keuls post hoc test.

1.2.3. Mechanistic studies

An attempt was made to determine the mechanism behind the potentiation of
clonidine antinociception by MD-354 (21) in the tail-flick assay. Neither imiloxan (98), an
~ ~ ~ ~ - a d r e n o c eantagonist,
ptor
the 5-HT3 receptor antagonist tropisetron (33), nor yohimbine
(39), an a2-adrenoceptor antagonist, produced a statistically significant antinociceptive
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effect in the tail-flick assay when administered alone. Doses of 0.03, 0.1, 0.3, 1.0, and 3.0
mglkg of imiloxan (98) produced <5% MPE when administered 55 min prior to testing
(data not shown). Tropisetron (33) produced 4 0 % MPE at doses 0.0000001, 0.000001,
0.00001, 0.0001, 0.001, and 0.0035 mgkg when administered 50 min prior to testing (data
I

not shown). Yohimbine (39) produced <1% MPE at doses of O.1,0.5, and 1.0 mglkg when
administered 60 min prior to testing (data not shown). Pretreatment with imiloxan (0.033.0 mglkg) significantly attenuated the potentiation of clonidine (0.25 mg/kg) by 29 (0.03
rnglkg) (Figure 25). Interestingly, doses of 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg of imiloxan
potentiated the antinociceptive actions of clonidine (0.25 mglkg) (Figure 26).

+ Clonidine
Imiloxan Dose (mg/kg)
+ Combination

Figure 25.

Effect (f S.E.M.) of subcutaneous imiloxan on the antinociceptive actions of a

combination (of subcutaneous clonidine (0.25 mg/kg) and compound 29 (0.03 mg/kg)) in the tailflick assay (n = 8-10 miceltreatment). Asterisks denote significant differences compared to the
combination control group; *P<O.OS,**P<O.Ol, and ***P<0.001; one-way ANOVA followed by
Newrnan-Keuls post hoc test.

Clonidine 0.03
0.25 mgkg

0.1

0.3

1

3

mil ox an Dose (mglkg)
+ Clonidine 0.25 mglkg
Figure 26. Potentiation of the antinociceptive actions (fS.E.M.) of subcutaneous clonidine (0.25

mglkg) by subcutaneous imiloxan in the tail-flick assay (n = 6-15 miceltreatment). Asterisks denote
significant differences compared to control group; *P<0.05; one-way ANOVA followed by
Newman-Keuls post hoc test.

Pretreatment with the 5-HT3 antagonist tropisetron (33) (0.00001 and 0.0001
mglkg) significantly attenuated the increase in the tail-flick latency produced by s.c.
administration of 29 (0.03 mgkg) in combination with clonidine (0.25 mgkg; Figure 27).
However, doses of 0.001 to 0.1 mgkg of tropisetron (33) did not significantly attenuate the
effect of the 29lclonidine combination (Figure 27). Interestingly, doses of 0.0000001,
0.00000 1, 0.00001, 0.0001, 0.00 1, 0.02, and 0.1 mglkg potentiated the antinociceptive
actions of clonidine (0.25 mgkg) (Figure 28) although the effects were statistically
significant only following doses of 0.02 and 0.1 mgkg of tropisetron. Because both 29

Tropisetron Dose (mglkg)
+ Combination

Figure 27. Effect (f S.E.M.) of subcutaneous tropisetron on the antinociceptive actions of a

combination (of subcutaneous clonidine (0.25 mglkg) and compound 29 (0.03 mgkg)) in the tailflick assay (n = 8-10 miceltreatment). Asterisks denote significant differences compared to the
combination control group; *P<0.05 and**P<O.Ol; one-way ANOVA followed by Newman-Keuls
post hoc test.

and tropisetron (33) potentiate the antinociceptive actions of clonidine, a combination of a
low, non-potentiating dose of 29 and a low, non-potentiating dose of tropisetron (33)
should potentiate the action of clonidine. The EDs0 dose for the potentiation of clonidine
by tropisetron was calculated to be 0.0035 mglkg (calculated using the results from the
three highest doses shown in Figure 28). Administered with 0.25 m g k g of clonidine,
0.0035 m g k g of tropisetron (33) produced 51% MPE (Figure 29). In other words, the

EDso dose for tropisetron (33) did not potentiate the action of clonidine. The half-maximal
dose for the potentiation of clonidine by 29 (i.e., 0.03 + 2 = 0.015 mgkg) when
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administered in combination with clonidine also failed to potentiate the antinociceptive
effect (i.e., 42 L 17 % MPE) (Figure 29). However, a combination of 0.0035 mg/kg of
tropisetron (33) plus 0.015 mg/kg of 29 in combination with 0.25 mglkg of clonidine
produced an effect (79 f 12 % MPE; Figure 29) that was stsltistically significant relative to
the effect of clonidine alone.

Clonidine lom7 10"
lo4 0.001 0.02
0.25 mglkg
Tropisetron Dose (mg/kg)
+ Clonidine 0.25 mg/kg

0.1

Figure 28. Potentiation of the antinociceptive actions (+ S.E.M.) of subcutaneous clonidine (0.25

mglkg) by subcutaneous tropisetron in the tail-flick assay (n = 6-8 miceltreatment). Asterisks

denote significant differences compared to control group; *P<0.05; one-way ANOVA followed by
Newman-Keuls post hoc test.

Clonidine Clonidine Clonidine Clonidine Clonidine Clonidine
0.25 mgkg 0.25 mg/kg 0.25 mgkg 0.25 mg/kg 0.25 mg/kg 0.25 mgkg
+ 29
+ 29
+ 33
+ 33
+ 29
0.03 mg/kg 0.015 mg/kg 0.1 mgtkg 0.0035 mg/kg 0.015 mg/kg
+ 33
0.0035 mgtkg

Figure 29. Effect (k S.E.M.) of tropisetron (33)(s.c.) and 29 (s.c.) on the antinociceptive actions of

clonidine (0.25 mgkg; s.c) and 29 (s.c.) in the tail-flick assay (n = 5-7 miceltreatment). Asterisks
denote significant differences compared to control group; *P<0.01, **P<0.001; one-way ANOVA
followed by Newman-Keuls post hoc test. Saline produced 6 f 4 % MPE.

Pretreatment with yohimbine (0.5 and 1 mglkg) significantly attenuated the effect
observed with the combination of 29 (0.03 mglkg) and clonidine (0.25 mglkg) (Figure 30).
Doses of 0.1, 0.5, and 1.0 mglkg of yohimbine did not significantly potentiate clonidine
(Figure 3 1).

29
+Clonidine

0.1

0.5

1

Yohimbine Dose (mglkg)
+ Combination
Figure 30. Effect (f S.E.M.) of subcutaneous yohimbine on the antinociceptive actions of a

combination (of subcutaneous clonidine (0.25 mglkg) and 29 (0.03 mgtkg)) in the tail-flick assay
(n = 8 miceltreatment). Asterisks denote significant differences compared to control group;

*P<0.05 and**P<O.Ol; one-way ANOVA followed by Newrnan-Keuls post hoc test.

Clonidine
0.25 mg/kg

0.1

0.5

1

Yohimbine Dose (mgkg)
+ Clonidine 0.25 mglkg
Figure 31. Potentiation of the antinociceptive actions (fS.E.M.) of subcutaneous clonidine (0.25

mglkg) by subcutaneous yohimbine in the tail-flick assay (n = 8-16 miceltreatment).
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In the tail-flick assay, 2.0 mglkg of morphine produced 39% MPE (Figure 32),
which was similar with that previously reported in the literature.'09 In a combination study,
doses of 0.003, 0.03, and 1.0 mglkg of 29 slightly potentiated the antinociceptive activity
of 2.0 mglkg of morphine (Figure 32).

The observed effect was not statistically

significant. However, a combination of 2 mg/kg of morphine plus 10 mg/kg of 29
significantly decreased the antinociceptive activity of morphine.

Morphine 0.003
2 mg/k

0.03

0.1

1

3

10

Compound 29 Dose (mg/kg)
+ Morphine 2 mgkg

Figure 32. Effect (f S.E.M.) of subcutaneous compound 29 doses administered in combination

with morphine (2 mglkg, s.c.) in the tail-flick assay (n = 6-8 miceltreatment). Asterisks denote
significant differences compared to control group; *P<0.05; one-way ANOVA followed by
Newman-Keuls post hoc test.

1.2.4. Spontaneous activity

Subcutaneous administration of 0.03 mglkg of 29 after 15, 30, and 45 min
produced saline-like effects in three main measures of locomotor activity. For example,
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after 45 min the measure of (i) total movements was recorded as 350 f 24 and 322 f 28 for
saline and 29, respectively; (ii) total movement time in seconds was 1472

+ 143 for saline

and 1411 f 165 for 29; (iii) total movement distance in centimeters was 5 175 f 919 and
4470

+ 625 for saline and 29, respectively.

Subcutaneous administration of 29 (0.03

mglkg) in combination with subcutaneous clonidine (0.25 mglkg) after 15, 30, and 45 min
produced clonidine-like effects in three main measures of activity. After 45 min the
measure of (i) total movements were recorded as 123 f 22 and 164 f 154 for clonidine and

29 + clonidine, respectively; (ii) total movement time in seconds was 404 5 76 for
clonidine and 632 f 154 for 29 + clonidine; (iii) total movement distance in centimeters
was 1287 f 272 and 2039

+ 480 for clonidine and 29 + clonidine, respectively.

1.3. The carbamate analog of MD-354,113

1.3.1. Tail-flick assay
The antinociceptive properties of the carbamate analog of MD-354 (21), 113, were
compared with those of MD-354. Compound 113 failed to produce a statistically
significant antinociceptive effect when administered alone (Figure 33). Compound 113
produced <5% MPE at doses 0.3, 1.O, 6.0, and 10 mglkg when administered 45 min prior
to testing (Figure 33). To determine an optimal pretreatment time, selected 113 doses were
examined using various pretreatment times (in addition to the 45-min pretreatment time)
but did not produce >lo% MPE (data shown in Figure 34 for 1 mglkg of 113).

Compound 113 Dose (mgtkg)
Figure 33. Effect (f S.E.M.) of 113 doses administered s.c. 45 min prior to examination in the

tail-flick assay (n = 6-8 rniceltreatment) as compared to saline control (6 f 4% MPE). Note scale
of y axis.

20 min

45 min

90 min

120 min

Compound 113 Dose (1.0 mgtkg)
Figure 34. Effect (f S.E.M.) of a 113 dose (1 mglkg, s.c.) administered 5 to 120 min prior to

examination in the tail-flick assay (n = 6-8 rniceltreatment) as compared to saline control (6 If: 4%

MPE). Note scale of y axis.

1.3.2. Combination studies

In the tail-flick assay, doses of 0.3, 1.0, 3.0, 6.0, and 10 mgkg of 113 potentiated
the antinociceptive actions of clonidine, when tested 45 min after administration (Figure
35), but the effect was statistically significant only after the 1.0 and 10 mglkg doses. To
I

determine the optimal pretreatment time, a dose of 1.0 mglkg of 113 with clonidine (0.25
mglkg) was examined using various pretreatment times (in addition to the 45 min
pretreatment time). The 113lclonidine combination was most effective following a 113
pretreatment time of 5 to 90 min (Figure 36).

Clonidine
0.25 mg/kg

0.3

1

3

6

10

Compound 113 Dose (mg/kg)
+ Clonidine 0.25 mgtkg
Figure 35. Potentiation of the antinociceptive actions (fS.E.M.) of clonidine (0.25 mglkg, s.c.) by

subcutaneous 113 in the tail-flick assay (n = 7-9 miceltreatment) 45 min post administration of
compound 113. Asterisks denote significant differences compared to control group; *P<0.05; oneway ANOVA followed by Newman-Keuls post hoc test.

Clonidine 5 min 20 min 45 min 90 min 120 rnin
0.25 mglkg
Compound 113 Dose (1.0 mg/kg)
+ Clonidine 0.25 mgkg
Figure 36. Potentiation of the antinociceptive actions (f S.E.M.) of clonidine (0.25 mgkg, s.c.) by

113 (1.0 mglkg, s.c.) when administered 5 to 120 min prior to examination in the tail-flick assay (n
= 8-9 miceltreatment). Asterisks denote significant differences compared to control group;

*P<0.05; one-way ANOVA followed by Newman-Keuls post hoc test.

1.4. N-(3-Methoxypheny1)guanidine (26)

1.4.1. Tail-flick assay
The antinociceptive actions of the methoxy counterpart of MD-354, 26, were
compared with those of MD-354. N-(3-Methoxypheny1)guanidine failed to produce a
significant antinociceptive effect when administered alone (Figure 37). Compound 26
produced

<lo% MPE at doses 0.03,0.3,1.0,3.0,6.0,10,and 30 mglkg when administered

45 rnin prior to testing.

1

3

6

10

30

Compound 26 Dose (mglkg)

Figure 37. Effect (fS.E.M.) of subcutaneous 26 doses administered 45 rnin prior to examination
in the tail-flick assay (n = 5-7 miceltreatment) as compared to saline control (6 f 4% MPE). Note
scale of y axis.

1.4.2. Combination studies
In the tail-flick assay, a combination of the ED5()dose of clonidine (0.5 mglkg) plus
inactive doses of 26 (0.03, 0.3, 1.0, 3.0, 6.0, 10, and 30 mgkg) potentiated the
antinociceptive effect in mice (MPE = 50-100%; Figure 38) but this increase was not
statistically significant except at doses of 0.3 and 6 mgkg of 26. A lower dose of
clonidine (0.25 mglkg) in combination with doses (0.3, 1.0, and 10 mglkg) of 26 did not
result in statistically significant potentiation of the antinociceptive effect (3 1-47% MPE;
Figure 39).

Clonidine 0.03
0.5 mg/kg

0.3

1

3

6

10

30

Compound 26 Dose (mgkg)
+ Clonidine 0.5 mglkg
Figure 38. Potentiation (f S.E.M.) of the antinociceptive actions of clonidine (0.5 mgtkg, s.c.) by

subcutaneous 26 in the tail-flick assay (n = 7 rniceltreatment). Asterisks denote significant
differences compared to control group; *P<0.05; one-way ANOVA followed by Newrnan-Keuls
post hoc test.

Clonidine
0.25 mg/kg

0.3

1

10

Compound 26 Dose (mgkg)
+ Clonidine 0.25 mglkg
Figure 39.

Effect (+ S.E.M.) of subcutaneous 26 doses administered in combination with

clonidine (0.25 mgkg, s.c.) in the tail-flick assay (n = 7 miceltreatment).
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2. Discussion
MD-354 (21) binds selectively both to 5-HT3 receptors and a2~-adrenoceptors,and
since both receptor populations have been implicated as playing a role in nociception, the
antinociceptive actions of MD-354 were evaluated.

It was previously shown in our

laboratory that MD-354 is inactive in the mouse tail-flick assay (Figure 10). Interestingly,
MD-354 potentiated the antinociceptive actions of an inactive dose of clonidine (Figure
1 1). Based on these results, the purpose of the present study was to examine MD-354 in a

different pain model, and to investigate its potential mechanism(s) of action accounting for
its potentiating effect on clonidine analgesia. One of the first studies conducted was to
determine whether MD-354 (21) is active in a different thermal pain test (i.e., hot-plate
assay). Clonidine was used as a positive control and evaluated in the hot-plate assay (ED5'

= 0.8 mglkg). The results obtained (Figure 13) were consistent with those reported in the
literature.''' Subsequently, MD-354 was evaluated in the mouse hot-plate assay. As in the
tail-flick assay, MD-354 did not produce any antinociceptive activity (Figure 14).
However, unlike what was seen in the tail-flick assay, MD-354 did not potentiate the
antinociceptive activity of clonidine in the mouse hot-plate assay (Figures 15 and 16).
There are several possible explanations for these differences. The tail-flick assay might
involve different receptor subpopulations or a different receptor mechanism than the hotplate assay. For instance, the tail-flick assay involves spinal receptors,95 whereas the hotplate assay involves supraspinal receptors.98 It has been suggested that supraspinal 5-HT3
receptors might not be involved with spinal analgesia.4' This was supported by a study
showing that the nonselective 5-HT3 receptor agonist, 2-methyl-5-HT did not produce
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antinociception when administered directly into the brain.4' Therefore, if supraspinal 5HT3 receptors are not involved with nociception, then any possible antinociceptive activity
observed with the arylguanidines in the hot-plate assay would primarily involve non-5-HT3
supraspinal receptors. Another possibility could be that there is a low density of a2Badrenoceptors present in the brain, and/or that MD-354 may not reach these receptors.
Since there is only a small number of supraspinal a2~-adrenoceptors61-63
and supraspinal 5HT3 receptors,41these might not be involved in nociception; this could possibly explain
why MD-354 does not potentiate clonidine in the mouse hot-plate assay. Differences
might also be related to the fact that MD-354 is not a very lipophilic agent and
distributional factors could be involved. MD-354 has an experimentally determined Log P
value of - 0 . 6 4 , ~indicating
~
that it might have difficulty penetrating the blood-brain barrier.
The carbamate derivative of MD-354, 113, was synthesized and examined to study
this factor. In theory, the more lipophilic 113 should more readily penetrate the bloodbrain barrier than MD-354 (21), and be subsequently hydrolyzed by brain tissue esterases
to MD-354. Compound 113 produced an effect similar to that of MD-354. As reported for
MD-354,Io3 compound 113 (doses of 0.3 to 10 mglkg) did not produce antinociceptive
effects when administered 5 to 120 min prior to testing in the mouse tail-flick assay
(Figures 33 and 34). This suggests that 113 might be rapidly hydrolyzed shortly after
administration. When administered in combination with clonidine (0.25 mglkg), however,

113 potentiated the antinociceptive actions of clonidine (Figure 35) much in the same
manner as did MD-354.

Previously we have shown that MD-354 potentiates the

antinociceptive effect of clonidine in a bell-shaped manner (Figure 11).'03 Re-examination
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of 1 mglkg of MD-354 (MPE = 1%) in combination with clonidine (0.25 mglkg; MPE =
13%) resulted in a supraadditive (statistically significant) antinociceptive effect (MPE =
84%; data not shown). Furthermore, these new data clearly indicate that a potentiation of
antinociceptive actions of clonidine by MD-354 occurs in a biphasic manner; this was also
seen for its carbamate analog 113. Overall, these results suggest that 113 may be
hydrolyzed to MD-354 in the periphery and behaves in the same manner as MD-354. The
potentiating effect of clonidine with 113 was also examined at various pretreatment
intervals (5 to 120 min) before the test (Figure 36). This might give an idea of how fast
113 is hydrolyzed in vivo and how long the observed potentiating effect lasts. When 113
was administered 15 min after clonidine and 5 min before the test, the effect was similar to
when 113 was administered 45 min before the test (Figure 36). Although, the results
suggest that 113 is probably hydrolyzed within at least 5 min of administration, the
potentiating effect lasts up to 120 min, even though at 120 min the 113lclonidine
combination produced a lower %MPE. Further studies will be required to examine the rate
of hydrolysis of 113 in vivo. In any event, 113 seems to behave much like its parent: MD354.

It would seem that the carbamate is too rapidly hydrolyzed to show effects

substantially different than those seen with MD-354. Therefore 113 was not examined in
the mouse hot-plate assay. The concept, however, is still a valid one. Future studies might
target carbamate analogs with bulkier substituents that are not as rapidly hydrolyzed as

113.
Next, mechanistic studies were conducted to help determine which pathway, 5-HT3
andlor a2B-adrenoceptors, is responsible for the potentiation of clonidine analgesia by
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arylguanidines.

Some of these studies utilized structurally modified arylguanidines

whereas other studies utilized 5-HT3 and adrenoceptor antagonists. In order to h l l y
understand which pathway is involved, several analogs of MD-354 (21) with different
binding profiles from MD-354 were studied. The first approach was to determine the
importance of 5-HT3 receptors in the potentiation of the antinociceptive actions of
clonidine by arylguanidines. A MD-354-related analog, 29, with a different binding
profile was examined. Compound 29 binds with about 50-fold higher affinity than MD354 at 5-HT3 receptors, and with similar affinity at a2B-adrenoceptors. However, unlike
MD-354, 29 does not show subtype selectivity for a2-adrenoceptors (Table 10).
Compound 29 alone did not produce an analgesic effect when administered 45 min before
the test in the tail-flick assay (Figure 20).

When administered in combination with

clonidine, 29 (0.3 mg/kg) potentiated the antinociceptive actions of clonidine (Figure 23)
and was about as effective as 1 mg/kg of MD-354. A much lower dose of 29 (0.03 mg/kg)
still produced potentiation of the clonidine effect. That is, 29 is at least 33 times more
potent than MD-354 in potentiating the antinociceptive actions of clonidine. Since 29 is 50
times more potent than MD-354 in binding at 5-HT3 receptors, this might explain the
comparatively greater potency of 29 relative to MD-354 in potentiating clonidine's
antinociceptive actions.

In theory, if the potentiating effect of clonidine by MD-354

primarily involves 5-HT3 receptors then 29 should be more potent than MD-354 in
potentiating clonidine. If a2B-adrenoceptorsprimarily mediated the potentiating effect of

Table 10. Binding Data for MD-354 (21), 29, and 26 at 5-HT3 and a2-Adrenoceptors.103,l 1 1

Ki (nM)

Adrenocevtors

clonidine, then 29 should have a similar potency relative to MD-354. Because 29 is more
potent in potentiating clonidine than MD-354, this further suggests that 5-HT3 receptors
may be involved in the potentiation of clonidine by arylguanidines. However, the
involvement of a2-adrenoceptors cannot be ruled out. Compound 29 also has a higher
affinity for a2,4- and a2c-adrenoceptor subtypes than MD-354 (Table 10). Compound 29 is
about 25 times more potent than MD-354 in binding at a2A-adrenoceptorsand 5 times
more potent in binding at a2c-adrenoceptors.

Since it has been shown that the a2,4-
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adrenoceptor subtype plays a role in antinociception, the increase in potency might also
involve the activation of a2A-adrenoceptors. It might also be noted that 29 is more
lipophilic than MD-354 ( 2 1 ) ; ~hence,
~
29 might be more potent than MD-354 because
more of it reaches supraspinal sites. Compound 29 was also studied in the mouse hot-plate
I

assay. The results were similar to that of MD-354, when 29 (0.3 mglkg) was administered
in combination with doses of 0.25 and 0.5 mglkg of clonidine, in that 29 did not potentiate
the antinociceptive activity of clonidine. Interestingly, 29 significantly potentiated the
antinociceptive activity of the EDs0 dose of clonidine (0.8 mglkg) in the mouse hot-plate
assay (Figure 24). These results suggest that 29 could be liphophilic enough to cross the
blood-brain barrier and reach supraspinal sites. Compound 29 possesses higher affinity for
and
- a2c-adrenoceptors than MD-354 and this could also explain the
5-HT3 receptors, a 2 ~
potentiation of clonidine in the mouse hot-plate assay
Another phenylguanidine, 26, was examined for possible antinociceptive actions in
the tail-flick assay. Compound 26 lacks significant affinity for 5-HT3 receptors but binds
nearly equally well at the three different subpopulations of a2-adrenoceptors (Table 10).
Furthermore, it binds with only several-fold lower affinity than 29 at each of the
adrenoceptor subtypes. Compound 26 did not produce antinociception when administered
alone (Figure 37). Interestingly, 26 did not potentiate the antinociceptive actions of an
inactive dose of clonidine (0.25 mglkg) (Figure 39). The lack of potentiating effect of 26
on the antinociceptive action of clonidine can be directly attributed to its low affinity for 5HT3 receptors. Methoxy-compound 26 binds with 46-fold and >2,000 fold lower affinity
affinity might also
than MD-354 (21) and 29, respectively. Its reduced ~t~~-adrenoceptor
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play a role here.

Interestingly, 26 (at doses 0.3 and 6.0 mglkg) potentiated the

antinociceptive activity of the EDso dose of clonidine (0.5 mglkg) (Figure 38).
In the antagonist studies conducted, the potentiating effect of 29 in combination
with clonidine was significantly antagonized by the 5-HT3 antagonist tropisetron (doses
0.0000 1 and 0.000 1 mglkg), the a2~-adrenoceptorantagonist imiloxan (doses 0.03 to 3.0
mglkg), and the nonselective a2-adrenoceptor antagonist yohimbine (doses 0.5 and 1.0
mglkg). The non-selective a2-adrenoceptor antagonist yohimbine completely abolished
the potentiating effect of 29 on clonidine (Figure 30). This observation is fairly simple to
explain. Because clonidine is believed to produce its antinociceptive effects via an a 2 adrenoceptor rnechani~rn,~
unavailability of a2-adrenoceptors (by yohimbine blockade)
would be expected to result in inactivity. Clonidine, alone or in combination with an
inactive arylguanidine, would not be expected to show any antinociceptive effect in the
presence of yohimbine.
The effect of clonidine (or clonidinelarylguanidine combinations) with tropisetron
or imiloxan is more complex, and might be dose related. Results with tropisetron and
imiloxan support the concept that the potentiation of clonidine by arylguanidines might
involve both 5-HT3 and a2B-adrenoceptors.The a2B/a2c-adrenoceptorantagonist imiloxan
failed to block the potentiating effect of MD-354 (21) on clonidine a n t i n o c i ~ e ~ t i o n . ' ~ ~
However, imiloxan was shown to potently antagonize the potentiating effect of 29 (Figure
25).

The different results will require additional study, but they certainly suggest

involvement of a2Bla2c-adrenoceptorsin the action of 29. However at doses of 0.3 and 3.0

1I6

mglkg, imiloxan (98), in the absence of 29, potentiated the antinociceptive activity of
clonidine (0.25 mglkg).

The potentiating effect of clonidine by imiloxan might be

explained by several possibilities. Clonidine binds nonselectively at the three a 2 adrenoceptor subtypes. It has been shown that both (2.2~-and a2B-adrenoceptorsubtypes
I

are involved with a n t i n o c i ~ e ~ t i oWhen
n . ~ ~ given
~ ~ in combination with clonidine, imiloxan
could bind to a2B/2c-adrenoceptorsand prevent clonidine from binding at these receptors.
This would allow clonidine to bind at more spinal and supraspinal ~t~~-adrenoceptors
than
before and could possibly potentiate its antinociceptive actions. Also, a2A-adrenoceptors
mediate the sedative effects caused by ~lonidine.'~
Therefore, if more a2A-adrenoceptors
are being activated then this could possibly potentiate the sedative effect as well. An
increase in sedation might be mistaken for an increase in antinociceptive properties. There
are several approaches that could be used to determine if sedative effects are involved in
the enhancing effect of clonidine antinociception by imiloxan. One approach is to examine
imiloxan in combination with clonidine in the locomotor activity assay. If imiloxan does
not potentiate the locomotor effects of clonidine, then this could suggest that sedative
effects are not responsible for the enhancing effect of clonidine's antinociceptive action by
imiloxan. Another approach is to try to block the greater than additive effect of imiloxan
and clonidine with an a2~-adrenoceptorantagonist (e.g. BRL 44408).
Evidence was obtained that 5-HT3 receptors also play a role. That is, the 5-HT3
antagonist tropisetron was able to block the potentiation of clonidine antinociception by 29
(Figure 27). Interestingly, however, administration of tropisetron potentiated the
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antinociceptive effects of clonidine in the absence of 29 (Figure 28). It might be argued
that 29, at least in part, potentiates the effect of clonidine by a 5-HT3 agonist mechanism;
this is consistent with the observation that the effect of clonidinel29 is blocked by the 5HT3 antagonist tropisetron. It is much more difficult to reconcile the observation that
tropisetron by itself potentiates the action of clonidine. Overall, the results imply that 5HT3 antagonists are capable of potentiating the antinociceptive actions of clonidine.
Evidently, this is more complex than it would first seem to be. Taken together, the results
of the present investigation suggest that arylguanidines potentiate the antinociceptive
actions of clonidine via both an a2-adrenoceptor and 5-HT3 receptor mechanism. Although
the arylguanidines might behave as a2-adrenoceptor agonists (or partial agonists), the
specific a2-adrenoceptor subtype(s) involved remains to be elucidated.

Several of the

studies argue in favor of a role for 5-HT3 receptors; but here, it is unclear whether the
agents act via a 5-HT3 agonist or antagonist (or both) mechanism.
Surprisingly, at doses 0.02 and 0.1 mglkg, tropisetron potentiated

the

antinociceptive actions of clonidine. These results further suggest that the mechanism of
antinociception via 5-HT3 and a2-adrenoceptors are interrelated. It has been shown that
the combination of 5-HT (1) and norepinephrine (36) produces a synergistic effect on
a n t i n o c i ~ e ~ t i o n .Because
~ . ~ ~ tropisetron is both a 5-HT3 and 5-HT4 antagonist, another
explanation is that tropisetron is blocking both 5-HT3 and 5-HT4 receptors and the
antagonist activity at one or both of these serotonin receptors could influence levels of 5HT. The available 5-HT could mediate the release (e.g. via heteroreceptors) of other
neurotransmitters which activate their corresponding descending inhibitory systems (e.g.
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NE, G A B A ) . ~ , Serotonin,
'~
by interacting with 5-HT3 receptors, can also modulate the
release of other neurotransmitters and neuropeptides (i.e., dopamine, acetylcholine,
Another possibility could be that %-adrenoceptor
GABA, substance P, ch~lec~stokinin).~'
antagonists block the antinociception mediated by 5-HT3 receptors because the two
systems are functionally related.
The effect of the EDso dose of the potentiating dose of tropisetron (33) and half of
the potentiating dose of 29 in combination with clonidine (43) was studied. In theory
because both tropisetron and 29 potentiate clonidine when administered alone, the low
doses of tropisetron and 29 together should potentiate clonidine in a similar manner. An
EDso dose of 0.0035 mglkg of tropisetron and half the active dose of 29 (0.015 mglkg)
potentiated the antinociceptive actions of clonidine in a similar manner as the 29lclonidine
combination. These results suggest that 29 is potentiating clonidine in the same manner as
tropisetron (i.e., via a 5-HT3 receptor antagonist mechanism). These findings of tropisetron
and 29 potentiating clonidine could be used clinically. Since tropisetron is already being
used as an antiemetic, using tropisetron with clonidine, or using the three agents (i.e.,
tropisetron, clonidine, and an arylguanidine) in combination could be clinically useful in
the treatment of pain associated with cancer.
The results with 5-HT3 and/or azB-adrenoceptor antagonists show that the
potentiating effect of 29 with clonidine might involve a biphasic mechanism. This means
that at extremely low doses, 5-HT3 receptors might be involved and that at higher doses,
azB-adrenoceptorscould be involved in the action of.29. It might be noted that 5-HT3
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receptor ligands commonly show potent actions (i.e., at sub-mglkg doses) in a variety of
pharmacological assays.42

Clonidine

(43), a

nonselective

a2-adrenoceptor agonist,

potentiates

the

antinociceptive actions of morphine but the exact adrenooeptor population responsible is
still unknown.90 Since the potentiation of clonidine by 29 might involve a2-adrenoceptors
via an agonist mechanism, 29 was also examined in combination with morphine in the tailflick assay. In theory, if the potentiating effect of 29 involves a2-adrenoceptors as with
clonidine, then 29 should potentiate the antinociceptive actions of morphine. Compound

29 potentiated the antinociceptive effect of morphine (2 mg/kg) (Figure 32) only at doses
of 0.003, 0.03, and 1 mglkg of 29 but the effect was not statistically significant.

In

contrast, doses of 0.1 and 3 mglkg of 29 slightly attenuated the antinociceptive action of
morphine (2 mg/kg); but here, too, the effect was not statistically significant. However a
dose of 10 mglkg of 29 blocked the actions of morphine and these results were statistically
significant (Figure 32). The studies of 29 in combination with morphine can be explained
in several ways. As mentioned earlier, co-administration of a2-adrenoceptor agonists and
opioid agonists produce a synergistic effect.90These results suggest that certain doses of 29
possibly potentiate morphine's antinociception via an a*-adrenoceptor agonist mechanism.
Earlier studies also showed that i.t. or i.c.v. administered morphine produces
n.~~
antinociception that can be blocked by the 5-HT3 antagonist t r ~ ~ i s e t r oConsequently,
any adrenergically-mediated potentiating effects of 29 might be counteracted by the
antagonist actions of 29 at 5-HT3 receptors if 29 is a 5-HT3 partial agonist. These results
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from the 29lmorphine studies suggest that 29 could be a 5-HT3 antagonist and an a*adrenoceptor agonist.
In the studies of MD-354 in combination with morphine, MD-354 (at doses 6 and
10 mglkg) did not seem to affect the antinociceptive action of morphine (1 mglkg) (Figure

18). However, a dose of 30 mglkg of MD-354 (21) attenuated morphine antinociception
but these results were not statistically significant. This difference in activity seen with
MD-354 and 29 might be explained by the compounds' different binding profiles. Since it
was proposed earlier that the attenuation seen with 29 might involve a 5-HT3 receptor
antagonist mechanism, the difference in activity could be due to the fact that 29 binds with
a 50-fold higher affinity at 5-HT3 receptors than MD-354 (Table 10). Also, different doses
were used in the two studies of MD-354 or 29 in combination with morphine. These
different doses could also explain the difference in activity with these two arylguanidines.
MD-354 was studied in combination with a lower dose of morphine (1.0 mglkg) than 29,
whereas 29 was studied with the EDso dose of morphine (2.0 mglkg). This difference
suggests that the higher dose of morphine (2.0 mglkg) could possibly require a lower dose
of 29 (1 0 mglkg) to block its antinociceptive actions. In the case of MD-354, using a dose
of 1.0 mglkg of morphine might require a higher dose of 30 mglkg of MD-354 to block its
antinociceptive actions. Further studies are needed to hlly explain the difference in
activity seen with MD-354 and 29 in combination with morphine.
Clonidine has been shown to produce sedation through activation of

a2-

adrenoceptors. h order to determine whether the potentiating effect by 29 is caused by
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antinociceptive effects or sedation, 29 was studied in a locomotor activity assay.
Compound 29 did not produce sedation in mice; this further suggests that 29 produces its
potentiating effect via an antinociceptive action and not a sedative effect. The combination
of 29 with clonidine was also studied and compared with the results of clonidine by itself.
The purpose of studying the combination was to see if 29 only potentiates clonidine's
antinociceptive actions or whether it also potentiates clonidine's sedative effects. The
combination of 29 and clonidine produced clonidine-like effects in the locomotor activity
assay and suggests that 29 selectively potentiates the antinociceptive, but not sedative
effects of clonidine.

This finding could be beneficial if 29 was clinically used in

combination with clonidine because sedation caused by clonidine is an undesired side
effect.

V. Conclusions

In summary, MD-354 is a rather selective 5-HT3/a2B-adrenoceptor ligand.
However, MD-354 was found to lack antinociceptive action by itself in the mouse tail-flick
assay,Io3and in the mouse hot-plate assay (present study). Although MD-354 potentiated
the antinociceptive effect of clonidine in the tail-flick assay, it did not potentiate the action
of clonidine in the hot-plate assay. These differences might reflect roles for spinal versus
supraspinal loci of action. Compound 113, a carbamate derivative of MD-354, produced a
similar biphasic dose-response curve as MD-354. This study suggests that 113 is rapidly
hydrolyzed in vivo to MD-354. Compound 29, which binds at 5-HT3 receptors with 50
times the affinity of MD-354, was extremely potent in potentiating the antinociceptive
effects of clonidine and was about 30 times more potent than MD-354. The potentiation of
clonidine by 29 can be blocked by the 5-HT3 receptor antagonist tropisetron, the

a2~-

adrenoceptor antagonist imiloxan, and the a*-adrenoceptor antagonist yohimbine. This
shows that both 5-HT3 and a2-adrenoceptors are involved in the potentiation of clonidine
antinociception by 29. Compound 26, an analog of MD-354 that lacks affinity at 5-HT3
receptors, did not potentiate the effect of an inactive dose of clonidine in the tail-flick
assay. However, 26 potentiated the effect of the EDso dose of clonidine (0.5 mglkg);
however, this potentiation was statistically significant only at doses of 0.3 and 6.0 mglkg.
The mechanism underlying clonidine potentiation requires further investigation;
122
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nevertheless a role for 5-HT3 and a*-adrenoceptors has been established. At least some
arylguanidines might be referred to as "dual-mechanism" potentiating agents of the
antinociceptive actions of clonidine. Another major finding of the present investigation is
that the 5-HT3 antagonist tropisetron, which is currently being used as an antiemetic agent
in cancer chemotherapy, can potentiate the analgesic effect of clonidine. Consequently,
clinicians should consider investigating combinations of these two clinically employed
agents to control the pain associated with certain types of cancer.

VI. Experimental
A. Synthesis

Melting points were determined in a glass capillary on a Thomas Hoover melting
point apparatus and are uncorrected.

Proton nuclear magnetic resonance ('H NMR)

spectra were obtained on a Varian Gemini 300 MHz spectrometer and peak positions are
given in parts per million (6) downfield from TMS. Elemental analysis was performed by
Atlantic Microlab Inc. (Norcross, GA), and determined values are within 0.4% of theory.
Column chromatography was performed on silica gel (Kiesel gel 40, 0.040-0.063 mm,
Merck) by flash chromatography. Routine thin-layer chromatography (TLC) was
performed on silica gel GHLF plates (250 p, 2.5 x 10 cm; Analtech Inc., Newark, DE).
Infrared spectra were obtained on a Nicolet Avatar 360 FT-IR spectrometer.

N-(3-Chloropheny1)guanidine Nitrate (MD-354) (21). Cyanamide (1.05 g, 33.7 mmol)
was added to a solution of 3-chloroaniline (115) (2.00 g, 15.7 mmol) and concentrated HC1
(1.60 mL) in absolute EtOH (15 mL). The stirred mixture was heated at reflux for 48 h.
The solvent was removed under reduced pressure and the resulting oil was cooled at 0 OC.
Water (15 mL) and ammonium nitrate (3.0 g) were added to give a precipitate which was
collected by filtration and recrystallized from H 2 0 and MeOH to give 21 (1.50 g, 41%) as
a white powder: mp 169-170 OC (lit.Io4mp 171-172 OC); 'H NMR (DMSO-d6) 6 7.32-7.36

(m, 4H, NH), 7.40-7.50 (m, 4H, ArH), 9.80 (s, 1H, H'NH).
124

125
N-(3-Methoxypheny1)guanidine Nitrate (26). Cyanamide (0.60 g, 15 mmol) was added

to a solution of m-anisidine (117) (1.20 g, 10 mmol) and concentrated HCl (0.8 mL) in
absolute EtOH (10 mL). The stirred reaction mixture was heated at reflux for 24 h. The
solvent was removed under reduced pressure and the resulting oil was cooled to 0 OC.
Water (5 mL) and ammonium nitrate (0.73 g) were added to give a precipitate which was
collected by filtration and recrystallized from H 2 0 and MeOH to give 26 (0.10 g, 19%) as
a white powder: mp 139-141 OC;

IH

NMR (DMSO-d6) 6 3.76 ( s, 3H, 0CH3), 6.80-6.88

(m, 3H, Ar-H), 7.31-7.37 (t, lH, ArH), 7.52-7.56 (m, 4H, NH), 9.85 (s, lH, 'NH). Anal.

Calcd for (CsHI1N30 HN03) C,H,N.
Methyl N-(3-chlorophenyl)guanidinecarboxylate Hydrochloride (113).

Method A.

Methyl chloroformate (0.17 mL, 2.15 mmol) in dry THF (2 mL) was added in a dropwise
manner to a solution of the fiee base of (3-chloropheny1)guanidine (21) (0.50 g, 2.15
mmol) and Et3N (0.60 mL, 4.30 mmol) in dry THF (100 mL) at 0 OC under an N2
atmosphere. The mixture was allowed to stir at 0 OC for 30 min and then at room
temperature for 16 h. The white precipitate was removed by filtration and the solvent was
removed under reduced pressure to give a mixture of two products which were separated
by column chromatography (silica gel, Kiesel gel 40, 0.040-0.063 mm) using CH2C121
MeOH (4: 1) as eluent. The free base of the desired product (113) was recrystallized from
EtOH to give 0.01 g (2%) of a white powder: mp 128-129 "C (lit.Io6mp 138-140 OC); 'H
NMR (CDC13) 6 3.63 (s, 3H, 0CH3), 7.10-7.36 (m, 4H, ArH), 7.38 (br. s, 2H, NH, NH ),
8.5 1 (s, 1 H, NH). Anal. Calcd for (C9HI0C1N3O2)
C,H,N.
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Method B. Calcium cyanamide (4.7 g, 58.7 mmol) was dissolved in H 2 0 (10 mL) and the

solution was added to methyl chloroformate (5.04 g, 53.3 mmol) in a dropwise manner.
The reaction mixture was allowed to stir for 20 min at 40-45 "C. The precipitate was
removed by filtration and 3-chloroaniline hydrochloride (115) (4.38 g, 26.7 mmol) was
added to the filtrate. Concentrated HC1 was added to the reaction mixture to obtain a pH of
3 and the mixture was heated at reflux for 30 min. The solvent was decanted off and the
solid was recrystallized from H 2 0 and EtOH to give 113 (0.19 g, 3%) as a white powder:
mp 159-160 "C; 'H NMR (DMSO-d6) 6 3.78 (s, 3H, CH3), 7.28-7.47 (m, 4H, ArH), 7.52
(br s, 2H, NH, NH), 8.81 (s, lH, NH). Anal. Calcd for (C9HloC1N302
-1.5HCl -0.25H20)
C,H,N.
2-Amino-5-chloro-3,4-dihydroquinazoline Hydrobromide (114). Compound 114 was

prepared according to a literature procedure.'07 Cyanogen bromide (0.63 mL, 1.87 mmol)
was added to a solution of 122 (0.25 g, 1.57 rnmol) in absolute EtOH (8 mL). The reaction
mixture was allowed to stir at room temperature for 1 h and heated at reflux for 5 h. The
solvent was removed under reduced pressure and H 2 0 (10 mL) was added to the resulting
residue. The suspension was extracted with CHC13 (3 x 10 mL) and the combined CHC13
portion was washed with brine (15 mL). The extract was dried with Na2S04 and the
solvent was removed under reduced pressure.

The product was recrystallized from

absolute EtOH to give 114 (free base; 0.25 g, 88%) as a powder: mp 234-235 "C (litIo7mp
221-223 "C); 'H NMR (DMSO-d6) 6 4.37 (s, 2H, CH2N), 6.5-7.0 (m, 3H, ArH).
Compound 114 (free base) was dissolved in Et20 and the solution was saturated with HBr
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gas. The precipitate was recrystallized from absolute EtOH to give 114 (0.07 g, 25%) as a
yellow powder: mp 234-235 OC (lit'07mp 241-243 OC); 'H NMR (DMSO-d6) 6 4.5 (s, 2H,
CH2N), 6.95-7.32 (m, 3H, 3 ArH), 7.60 (br. s, 2H, NH2), 8.33 (br. s, lH, NH), 10.66 (br. s,

Dimethyl N,N'-(3-chlorophenyl)guanidinedicarboxylate

(116). Methyl chloroformate

(0.17 mL, 2.15 mmol) in dry THF (2 mL) was added in a dropwise manner to a solution of

(3-chloropheny1)guanidine (21) free base (0.50 g, 2.15 mmol) and Et3N (0.60 mL, 4.30
mmol) in dry THF (100 mL) at 0 OC under an N2 atmosphere. The reaction mixture was
allowed to stir at 0 OC for 30 min and then at room temperature for 16 h. The white
precipitate was removed by filtration and the solvent was removed under reduced pressure
to give a beige solid which was recrystallized from absolute EtOH to give 116 (0.13 g,
21%) as a white powder: mp 160-161; 'H NMR (CDC13) 6 3.59 (s, 3H, 0CH3), 3.75 (s,
3H, 0CH3), 7.09-7.38 (m, 4H, ArH), 9.60 (br. s, 2H, NH, NH).

Anal. Calcd for

(C 1 lHl2ClN304) C,H,N2-Chloro-6-nitrobenzylbromide (119).

Compound 119 was prepared according to a

literature procedure.'07 N-Bromosuccinimide (8.54 g, 48 mmol) and benzoyl peroxide
(0.20 g, 0.80 mmol) were added to a solution of 2-chloro-6-nitrotoluene (118) (8.32 g, 48
mmol) in CC14 (100 mL). The stirred mixture was heated at reflux for 26 h under a 250Watt light bulb. The precipitate was removed by filtration and the solvent was removed
under reduced pressure.

The resulting solid was purified by column chromatography

(hexaneIEtOAc, 20: 1). The crude product was recrystallized from absolute EtOH to give
119 (8.25 g, 70%) as yellow crystals: mp 50-52 OC (lit.'07 mp 50-52 OC).
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N-(2-Chloro-6-nitrobenzy1)phthalamide (120). Compound 120 was prepared according

to a literature procedure.107Potassium phthalamide (7.91 g, 10.3 mmol) was added to a
stirred solution of 119 (2.35 g, 9.36 mmol) in DMF (20 mL). The exothermic reaction
mixture was allowed to stir for 2 h and cooled to room temperature. Chloroform (10 mL)
was added to the mixture which was then poured onto H20/ice (55 mL). More CHCI3 (20
mL) was added to the cooled mixture. The CHC13 portion was separated and washed with
0.2 N NaOH (26 mL) and brine (20 mL). The extract was dried (Na2S04)and the solvent
removed under reduced pressure to give 120 as yellow crystals. Compound 120 was used
without further purification or characterization in the synthesis of 121
2-Chloro-6-nitrobenzylamine (121).

Compound 121 was prepared according to a

literature procedure.'07 Compound 120 was dissolved in MeOH (15 rnL) and hydrazine
hydrate (0.52 g, 10.3 mmol) was added. The stirred mixture was heated at reflux for 1 h.
Water (10 mL) was added to the suspension and the MeOH was removed under reduced
pressure. The remaining solution was acidified with concentrated HC1 (10 mL) and heated
at reflux for 1 h. The precipitate was removed by filtration and 3 N NaOH was added to
the filtrate to obtain a pH of 12. Water (15 mL) was added to the solution and the mixture
was extracted with Et20 (4 x 50 mL) and the Et20 extract was washed with brine (50 mL).
The extract was dried with Na2S04. The solvent was evaporated under reduced pressure
and the crude product was purified using Kugelrohr distillation to give 121 (1.19 g, 68%)
as a yellow oil.

2-Amino-6-chlorobenzylamine (122). Compound 122 was prepared according to a
literature procedure.'07 Compound 121 (0.48 g, 2.57 -01)

and Raney Ni (0.71 g) in
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absolute EtOH (12 mL) were placed in a Pan- hydrogenator (psi = 3.5 atm) for 2 h. The
Raney Ni was removed by filtration and the solvent was removed under reduced pressure.
The resulting solid was dissolved in absolute EtOH (5 mL) and HCI gas was bubbled
through the solution, and it was allowed to stand at 0 OC for 1 h. The precipitate was
removed by filtration and recrystallized from an isopropanol, MeOH, Et20 mixture to give

122 HCl (0.42 g, 84%) as a powder: mp >240 "C (lit''' mp 263-265); 'H NMR (DMSOd6) 6 4.13 (s, 2H, CH2), 6.59 (s, IH, NH), 6.99-7.02 (m, 2H, ArH), 7.22-7.28 (m, IH,
ArH), 8.44 (br. s, IH, NH). Compound 122 HCl was dissolved in H 2 0 and 15% NaOH (2
mL) was added to obtain a pH of 13. The mixture was extracted with Et20 (3 x 40 mL)
and the combined Et20 portion was dried with Na2S04. The solvent was removed under
reduced pressure to give 122 (0.25 g, 61%) as a solid. Compound 122 was used without
further characterization in the synthesis of 114.

B. Behavioral studies
1. Animals

Male ICR mice (24-288) obtained from Harlan Laboratories (Indianapolis, IN)
were used throughout the study. Mice were housed in groups of five, with free access to
food and water. Animals were housed in an Association for Assessment and Accreditation
of Laboratory Animal Care (MALAC)-approved facility, and the study was approved by
the Institutional Animal Care and Use Committee of Virginia Commonwealth University.
Mice were allowed to adapt to the testing environment for at least 2 h prior to any

130
treatment. Animals were weighed on the day of the experiment(s) for the calculation of
drug dosages.

2. Drugs
Clonidine hydrochloride, morphine hydrochloride, tropisetron hydrochloride, and
yohimbine hydrochloride were purchased from Sigma-Aldrich Chemicals, (Milwaukee,
WI). Compounds 21,113, and 26 were synthesized as reported above. Compound 29 as its
HC1 salt was resynthesized as reported previously.30 Imiloxan hydrochloride was obtained
from Tocris (Ballwin, MO). All drugs were dissolved in physiological saline (0.9% sodium
chloride) and given in a total volume of 10 mL/1000 g body weight by subcutaneous (s.c.)
injection to the mice.

3. Behavioral assays
a) Hot-plate assay
The method is a modification of that described by Eddy and ~ e i m b a c h " and
~
Atwell and ~ a c o b s o n . Mice
' ~ ~ were placed into a 10-cm-wide glass cylinder on a hot-plate
(Columbus Hot-Plate Analgesia Meter) and the temperature was maintained at 55.0 "C. A
control response (6-10 s) was determined for each mouse before injection and a test latency
was determined after drug administration. In order to prevent any paw damage, 30 s was
used as the cutoff time. The antinociceptive response was calculated as percent maximum
possible effect (% MPE), where % MPE = [(test-control)/ (cutoff time-control)] x 100.
Groups of 5 to 26 mice were used for each dose and for each treatment.
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The protocol for testing the antinociceptive effects of these drugs was as follows:
15 min prior to S.C. administration of drugs, baseline latency was determined for each
mouse. Clonidine was administered 20 rnin prior to test. MD-354 (21) was administered
using various (10 to 90 min) pretreatment intervals. In a combination study of MD-354
/

with clonidine, MD-354 was administered 25 rnin prior to clonidine and 45 rnin before the
test. Compound 29 was administered 45 min prior to test. In a combination study, 29 with
clonidine, 29 was administered 25 rnin prior to clonidine and 45 min before the test.

b) Tail-flick assay
Antinociception was assessed by the tail-flick method of D'Amour and

as

modified by Dewey et a1.'I4 using a Columbus Tail-Flick Analgesia Meter. A control
latency (1.7-4.0 s) was determined for each mouse before injection, and a test latency was
determined after drug administration. A cutoff time of 10 s was used to avoid tissue
damage. The antinociceptive response was calculated in the same manner as in the hotplate assay. Groups of 5 to 16 mice were used for each dose and each treatment.
The protocol for testing the antinociceptive effects of these drugs was as follows:
15 rnin prior to S.C. administration of drugs, baseline latency was determined for each
mouse. MD-354 (21) was administered 45 min before test. In a combination study using
MD-354 with morphine, MD-354 was administered 15 min before morphine and 45 rnin
prior to the test. Compound 29 was administered 45 min before the test. In a combination
study using 29 with clonidine, 29 was administered 25 min before clonidine and 45 rnin
before the test. In a combination study using 29 and morphine, 29 was administered 15
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rnin before morphine and 45 min before the test. Tropisetron was administered 5 min
before 29 and 30 min prior to clonidine. Imiloxan was administered 10 rnin prior to 29 and
35 rnin before clonidine. Yohimbine was administered 15 min before 29 and 40 min prior
to clonidine.

Compound 113 was administered by using various (5 to 120 min)

pretreatment intervals.

In combination studies using 113 with clonidine, 113 was

administered 0 to 100 rnin prior to clonidine and 5 to 120 rnin before the test. Compound

26 was administered 45 min before the test. In combination studies using 26 and clonidine,
26 was administered 25 min before clonidine and 45 min prior to the test.

c) Spontaneous activity
Mice were placed into individual Tru Scan Infrared Locomotor Activity System
(Coulbourn Instruments, Allentown, PA) photocell activity cages (40 cm cube) after S.C.
administration of either 0.9% saline or 29 (0.03 mglkg). Ambulatory movement was
measured by the number of times the animal interrupted the infrared beams traversing the
cage for a period of 15 min. Measurements were taken 15, 30, and 45 rnin following drug
treatment. The analysis was focused only on main measures (three main measures: total
moves, move time, move distance) of activity to determine whether 29 (n = 6ldose)
depressed this action relative to saline (n = 6) control or whether 29 + clonidine (n =
6ldose) potentiated the depressed action relative to clonidine (n = 6). The pretreatment
time for clonidine was 5 min before the test.
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d) Statistical analysis
Data were analyzed statistically by an analysis of variance (ANOVA) followed by
the Newman-Keuls test for multiple post hoc comparison test. The null hypothesis was
rejected at the 0.05 level. For the time-course studies, each animal was used once. Data
were analyzed by one-way or a two-factor ANOVA as applicable. ED50values with 95%

CL for behavioral data were calculated by unweighted least-square linear regression as
described by Tallarida and ~ u r r a ~ . ' ' ~
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